Role of the prostaglandin E2 receptor EP1 in hypertensive end-organ damage by Bartlett, Christina Swan
ROLE OF THE PROSTAGLANDIN E2 RECEPTOR EP1 IN 
 
HYPERTENSIVE END-ORGAN DAMAGE 
 
 
By 
 
 
Christina S. Bartlett 
 
 
 
Dissertation 
 
Submitted to the Faculty of the 
 
Graduate School of Vanderbilt University 
 
in partial fulfillment of the requirements 
 
for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
In 
 
Pharmacology 
 
December, 2012 
 
Nashville, Tennessee 
 
 
 
Approved: 
 
Richard M. Breyer 
 
Brian E. Wadzinski 
 
Vsevolod V. Gurevich 
 
Ambra Pozzi 
 
Alfred L. George, Jr. 
 
 
ii 
 
ACKNOWLEDGEMENTS 
 
Completion of my doctoral work would not have been possible without the 
help of so many people.  First, I must thank my advisor and mentor, Dr. Richard 
Breyer.  Rich has always offered encouragement and advice on both a 
professional and personal level.  I am grateful for his patience and guidance 
throughout the last six years and serving as a great scientific role model.  I would 
also like to thank all the current and past members of the Breyer lab who have 
been instrumental in making my experience in the lab enjoyable.  In particular I 
am grateful to Jason Downey, who has been a sounding board of all crazy ideas 
and become a good friend. 
 I would like to acknowledge the Pharmacology Department and Division of 
Nephrology and Hypertension of Vanderbilt University for administrative and/or 
financial support. Additionally, I would like to acknowledge the remaining 
members of my committee Drs. Brian Wadzinski (chair), Seva Gurevich, Ambra 
Pozzi and Al George for making my committee meetings a valuable and 
pleasurable experience.  I would also like to acknowledge Dr. Jason Morrow, 
who was a member of my committee from 2007-2008. 
 There are a number of other people who have provided support for 
various aspects of my doctoral training.  I am grateful to Leslie Gewin for 
teaching me to perform uninephrectomies and all the members of the MMPC, 
especially Lianli Ma, for teaching me to perform intracarotid blood pressure 
measurements and help with various experiments.  Dr. Jeff Reese 
iii 
 
enthusiastically welcomed me into his lab space and taught me myography 
studies.  I am also grateful to the wonderful collaborators I have had the pleasure 
to work with; Drs. Roy Zent, Kelli Boyd, and Ray Harris.  Thank you all! 
 Finally, I would like to thank my friends and family; both in and out of 
Nashville, for helping me emotionally survive my graduate experience.  I am 
grateful for my parents who have given me unconditional love and support, and 
my best friend and sister, who I can always depend on to lend an ear.  There is 
no one who deserves more credit for this work than my husband, Robert.  Thank 
you for being my rock through all the ups and downs.  You always manage to 
bring a smile to my face and provide motivation and encouragement.  I am 
indebted to you. 
  
iv 
 
PUBLICATIONS 
 
 
Bartlett CS, Boyd KL, Harris RC, Zent R, Breyer RM. EP1 disruption attenuates 
end-organ damage in a mouse model of hypertension. Hypertension.  2012 Nov; 
60(5): 1184-91. 
Kapitsinou PP, Jaffe J, Michael M, Swan CE, Duffy KJ, Erickson-Miller CL, 
Haase VH.  Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis 
associated with acute kidney injury.  Am J Physiol Renal Physiol. 2012 May; 
302(9):F1172-9. 
Swan CE, Breyer RM.  Prostaglandin E2 modulation of blood pressure 
homeostasis: studies in rodent models. Prostaglandins Other Lipid Mediat. 2011 
Nov; 96(1-4):10-3. 
 
 
  
v 
 
TABLE OF CONTENTS 
 
Page 
ACKNOWLEDGEMENTS ...................................................................................... ii 
PUBLICATIONS .................................................................................................... iv 
LIST OF TABLES .................................................................................................. vii 
LIST OF FIGURES ............................................................................................... viii 
LIST OF ABBREVIATIONS ................................................................................... x 
Chapter 
I.  INTRODUCTION ............................................................................................... 1 
          History of hypertension ................................................................................ 1 
          Pathophysiology and consequences of hypertension .................................. 4 
          Prostaglandins: Biosynthesis and catabolism .............................................. 7 
          PGE2 Receptors: Pharmacological properties and signaling ...................... 10 
               EP1 receptors ........................................................................................ 10 
               EP2 receptors ........................................................................................ 12 
               EP3 receptors ........................................................................................ 15 
               EP4 receptors ........................................................................................ 16 
          PGE2 receptors as therapeutic targets ....................................................... 18 
               EP1 receptors ........................................................................................ 19 
               EP2 receptors ........................................................................................ 20 
               EP3 receptors ........................................................................................ 22 
               EP4 receptors ........................................................................................ 24 
          PGE2 receptors in blood pressure regulation .............................................. 26 
                Vasodepressor receptors ...................................................................... 28 
                Vasopressor receptors .......................................................................... 29 
                Consequences of hypertension ............................................................ 31 
          Objective ..................................................................................................... 34 
 
II. DISRUPTION OF EP1 ATTENUATES END-ORGAN DAMAGE IN A 
          MOUSE MODEL OF HYPERTENSION ...................................................... 36 
 
          Introduction ................................................................................................. 36 
          Experimental Procedures ........................................................................... 38 
          Results ........................................................................................................ 42 
          Discussion .................................................................................................. 60 
vi 
 
III. DISRUPTION OF EP3 IS PROTECTIVE AGAINST MORTALITY IN A  
          MOUSE MODEL OF HYPERTENSION ...................................................... 65 
 
          Introduction ................................................................................................. 65 
          Experimental Procedures ........................................................................... 67 
          Results ........................................................................................................ 70 
          Discussion .................................................................................................. 78 
 
IV. CONTRIBUTION OF THE EP1 RECEPTORS IN HYPERTENSIVE RENAL  
          DAMAGE .................................................................................................... 81 
 
          Introduction ................................................................................................. 81 
          Experimental Procedures ........................................................................... 84 
          Results ........................................................................................................ 87 
          Discussion .................................................................................................. 92 
 
V. CONTRIBUTION OF THE EP1 RECEPTOR IN DIABETIC RENAL  
          DAMAGE .................................................................................................... 96 
 
          Introduction ................................................................................................. 96 
          Experimental Procedures ........................................................................... 98 
          Results ....................................................................................................... 101 
          Discussion ................................................................................................. 106 
 
VI. SUMMARY AND FUTURE DIRECTIONS ...................................................... 110 
          Summary ................................................................................................... 110 
          Future directions ........................................................................................ 115 
 
BIBLIOGRAPHY .................................................................................................. 119 
  
vii 
 
LIST OF TABLES 
 
Table             Page 
1.1    Classification of hypertension ...................................................................... 5 
1.2    Pharmacological agents targeting mouse PGE2 receptors ........................ 13 
2.1    Echocardiography data at baseline and five days post-Ang II ................... 55 
  
viii 
 
LIST OF FIGURES 
 
Figure                    Page  
1.1     Biosynthesis of prostaglandins .................................................................... 9 
1.2     PGE2 receptors in blood pressure regulation .............................................. 27 
2.1     Nphx/DOCA-NaCl/Ang II induced substantial mortality in EP1+/+  
          mice   .......................................................................................................... 44 
 
2.2     Nphx/DOCA-NaCl/Ang II model induced aortic aneurysm formation .......... 46 
2.3     Aortic inflammation is observed in EP1+/+ and EP1-/- mice ....................... 47 
2.4     Aortic fibrosis is observed in EP1+/+ and EP1-/- mice ............................... 48 
2.5     Body weight increased during Nphx/DOCA-NaCl/Ang II treatment in  
          EP1+/+ mice ............................................................................................... 49 
 
2.6     Plasma alanine transaminase activity and body weight showed no 
          correlation in EP1+/+ mice .......................................................................... 50 
 
2.7     Modest renal damage is observed in EP1+/+ and EP1-/- mice .................. 53 
2.8     Mean arterial pressure is increased in EP1+/+, and blunted in EP1-/-,    
          mice ............................................................................................................ 57 
 
2.9     Hydralazine treatment reduced mortality in EP1+/+ but not EP1-/- mice .... 59 
3.1     The uninephrectomy/DOCA-NaCl/Ang II model resulted in significant           
          mortality ...................................................................................................... 71 
 
3.2     Body weight increased in EP3+/+ but not EP3-/- mice ............................... 73 
3.3     Both EP3+/+ and EP3-/- animals had significant increases in systolic blood 
          pressure ...................................................................................................... 75 
3.4     Modest end organ renal damage is observed in EP1+/+ and EP1-/-  
          mice ............................................................................................................ 76 
 
3.5     Quantitation of renal damage ..................................................................... 77 
4.1     Experimental Design of Nphx + Ang II induced renal damage ................... 85 
ix 
 
4.2     Hypertension was induced by Nphx + Ang II administration ....................... 88 
4.3     Heart and kidney weight were increased in both EP1+/+ and EP1-/- mice 
          after 6  weeks treatment with Nphx + Ang II ............................................... 90 
 
4.4     BUN was increased by Nphx + Ang II treatment......................................... 91 
4.5     ACR and GFR following treatment with Nphx + Ang II ............................... 93 
5.1     Induction of diabetes in mice ..................................................................... 100 
5.2     Diabetes was induced in all genotypes with low dose STZ treatment ....... 102 
5.3     MAP was increased by genetic deletion of eNOS, but not EP1 gene 
          disruption ................................................................................................... 104 
 
5.4     Albuminuria was significantly reduced by genetic disruption of EP1 in  
          diabetes ..................................................................................................... 105 
 
5.5     GFR was significantly reduced by deletion of eNOS in the presence, but  
          not absence, of EP1 receptor expression .................................................. 107 
 
 
  
x 
 
LIST OF ABBREVIATIONS 
 
AA  Arachidonic acid 
AAALAC Association for accreditation and assessment of laboratory animal  
care 
 
ACEi  Angiotensin converting enzyme inhibitor 
ACR  Albumin:creatinine ratio 
ALT  Alanine transaminase 
Ang II  Angiotensin II 
ARB  Angiotensin receptor blocker 
AT  Angiotensin II receptor 
BP  Blood pressure 
BUN  Blood urea nitrogen 
[cAMP]i Intracellular cyclic adenosine monophosphate 
CHF  Congestive heart failure 
CNS  Central nervous system 
COX  Cyclooxygenase 
cPLA2  Cytosolic phospholipase A2 
CVD  Cardiovascular disease 
DGLA  Dihomo-gamma-linolenic acid 
DN  Diabetic nephropathy 
DOCA  Deoxycorticosterone acetate 
EF  Ejection fraction 
EGFR  Epidermal growth factor receptor 
xi 
 
eNOS  Endothelial nitric oxide synthase 
EP  E-prostanoid receptor  
EPA  Eicosapentaenoic acid 
FS  Fractional shortening 
ESRD  End-stage renal disease 
GBM  Glomerular basement membrane 
GFR  Glomerular filtration rate 
GPCR  G protein-coupled receptor 
H/E  Hematoxylin and eosin 
ICV  Intracerebroventricular 
IVS  Intraventricular septum 
JNC  Joint National Committee 
Kim-1  Kidney injury molecule-1 
LVID  Left ventricular interior diameter 
LVPW  Left ventricular posterior wall 
LTs  Leukotrienes 
MAP  Mean arterial pressure 
mPGES Microsomal prostaglandin E synthase 
mRNA Messenger ribonucleic acid 
Ngal  Neutrophil gelatinase-associated lipocalin 
Nphx  Uninephrectomy 
NSAIDs Non-steroidal anti-inflammatory drugs 
PGs  Prostaglandins 
xii 
 
PGE2  Prostaglandin E2 
PGIs  Prostacyclins 
PTX  Pertussis toxin 
RAAS  Renin-angiotensin-aldosterone system 
SBP  Systolic blood pressure 
STZ  Streptozotocin 
TX  Thromboxanes
  
1 
 
CHAPTER I 
 
INTRODUCTION 
 
History of Hypertension 
 
In 1733, the idea of blood pressure (BP) was first credited to British 
veterinarian Stephen Hales who observed the pulsation of blood when inserting a 
pipe into the artery of a horse.  Hales concluded that pressure must be pushing 
the blood.  While blood pressure was an accepted idea, it was not until 1847 
when the first recording was made using a kymograph by Carl Ludwig.  Many 
years later, Samuel Karl Ritter von Basch invented the sphygmomanometer, 
which was further improved to a mercury filled sphygmomanometer with an 
inflatable cuff in 1896 by Scipione Riva-Rocci.  Massachusetts General Hospital 
was among the first to incorporate its use into routine checkups, courtesy of 
neurosurgeon Harvey Cushing.  Although the risks of high blood pressure were 
acknowledged by insurance companies, it was not until the 1960s that the 
medical community had wide acceptance of these dangers.  Until this time many 
experienced and prominent cardiologists considered high blood pressure to be 
an important compensatory phenomenon that should be left alone. 
 
The greatest danger to a man with high blood pressure lies in its discovery, 
because then some fool is certain to try and reduce it. – J.H. Hay, 1931 
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Hypertension may be an important compensatory mechanism which should not 
be tampered with, even were it certain that we could control it. 
– Paul Dudley White, 1937 
 
President Franklin Delano Roosevelt suffered and eventually died as a 
result of high blood pressure, and the progression of his disease is an eloquent 
example of the natural history of untreated hypertension (1).  In 1937, 54 year old 
Roosevelt had a BP of 162/98 mm Hg, though received no treatment to reduce 
his hypertension.  Within three years, his blood pressure had risen to 180/88 
mm Hg.  In 1941, his physician prescribed phenobarbital and massages, as his 
blood pressure had risen to 188/105 mm Hg.  Over the next three years, 
President Roosevelt suffered shortness of breath, drowsiness, and lethargy.  At 
the request of Roosevelt’s daughter, cardiologist Howard G. Bruenn examined 
President Roosevelt finding strong evidence of congestive heart failure (CHF) 
including pulmonary edema, an enlarged heart, left ventricular hypertrophy and 
proteinuria.  He treated Roosevelt by reducing his alcohol and cigarette use, 
limiting his activity, administering digitalis and implementing a low salt diet which 
helped to improve his symptoms.  That year Roosevelt’s blood pressure was as 
high as 230/140 mm Hg.  In 1945, his blood pressure had risen to 260/150 and 
on April 12, 1945 while sitting for a portrait President Roosevelt lost 
consciousness.  His blood pressure had risen to > 300/190 mm Hg and he died 
of a cerebral hemorrhage.   
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At this time there were very few options with regards to the treatment of 
hypertension and all had severe side effects.  The low salt diet had been 
suggested as a treatment in 1922 by Allen and Sherrill, though this received very 
little attention in the United States (2).  The Kempner rice diet published in 1944 
was demonstrated to significantly impact BP although this diet had very low 
compliance (3).  Other more radical therapies included inoculation with fever 
producting agents such as typhoid bacilli, or surgical procedures like 
sympathectomy and adrenalectomy (4).  The herb veratrum viride showed great 
promise for lowering blood pressure but had a very narrow therapeutic window.  
Dr. Edward Freis, a leader in antihypertensive treatment, began using the 
antimalarial drug pentaquine as a hypotensive drug (1).    
The 1950s were a time of great struggle with regards to acceptance of the 
dangers and need to treat hypertension in the medical community.  In 1955, 
Perera of Columbia Univerisity published conclusions from a study of 300 
patients suggesting hypertension is relatively benign and the label overused (5).  
Meanwhile, clinical evidence began accumulating demonstrating the benefit of 
lowering blood pressure, and the search for novel therapeutic agents boomed.  
Alternatives to the dangerous surgical procedures were discovered including 
sympathetic nerve blockers (phenoxybenzamine), ganglionic blockers 
(hexamethonium, pentolinium), peripheral adrenergic inhibitors (guanethidine), 
catecholamine reduction (reserpine) and vasodilators (hydralazine).  In 1957, a 
clinical trial began for a major antihypertensive agent still used today, 
chlorothiazide (6).   
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In the 1960s, the Framingham Heart Study showed a correlation between 
blood pressure and heart attacks, congestive heart failure, stroke and kidney 
damage (7).  The first Veterans Administration study showed antihypertensive 
therapy in patients with diastolic BP > 105 mm Hg was able to reduce the 
incidence of stroke, CHF, and kidney damage (8).  Propranolol began its clinical 
use in the early 1960s as the first of the beta blocker family.  The National High 
Blood Pressure Education Program was started as a way of informing the 
medical community and public of the dangers of high blood pressure and 
methods to treat it.  In 1977, the first report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) 
was published, setting the standards for blood pressure diagnosis and treatment 
(9).  These standards are updated regularly and JNC 8 is currently in 
development. 
 
Pathophysiology and Consequences of Hypertension 
 
Still today, hypertension is a prevalent disease which causes substantial 
morbidity and mortality in humans, and affects approximately 33 % of adults in 
the United States (10).   Roughly one-third of afflicted individuals are receiving 
treatment for hypertension, though only one-half of treated patients have their 
blood pressure under control.  Thus, prevention and treatment of hypertension is 
an important public health goal.   
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 Hypertension can be classified into several categories based on the 
degree of blood pressure elevation (Table 1.1) ranging from prehypertension 
(systolic 120-139 mm Hg/ diastolic 80-90 mm Hg) to Stage 2 hypertension 
(systolic ≥ 160 mm Hg/ diastolic ≥100 mm Hg) (11).  Alternatively, hypertension 
can be designated either essential or secondary, based on the root cause of the 
high blood pressure.  About 95 % of hypertensive adults have essential 
hypertension, meaning no secondary cause was discovered.  Secondary causes 
of hypertension can include renal, vascular, endocrine, neurogenic and drug or 
toxin induced hypertension.  
Following chronic elevated blood pressure, target end-organ damage to 
the aorta and small arteries, heart, kidneys, and retina can be observed.  Blood 
pressure is the product of cardiac output (stroke volume x heart rate) and 
systemic vascular resistance.  Thus, it is reasonable to conclude that patients 
 
 
Table 1.1  Classification of Hypertension 
 
     Systolic BP (mm Hg) Diastolic BP (mm Hg) 
Normal < 120 < 80 
Prehypertension 120-139 80-90 
Stage 1 140-159 90-99 
Stage 2 ≥ 160 ≥ 100 
For adults 18 years or older, based on recommendation of the JNC VII. 
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with hypertension may have increased cardiac output, increased vascular 
resistance, or both. Early in the course of disease, cardiac output is often 
elevated.  Over time, vascular stiffness and increased systemic vascular 
resistance plays a greater role (12).  This increases the afterload on the left 
ventricle, inducing left ventricular hypertrophy and dysfunction, which is an 
independent risk factor for sudden death and stroke.  Coronary artery disease is 
another cardiac consequence of hypertension.  At higher MAP the heart requires 
more oxygen to constrict, and lipid plaques in the arteries decrease coronary 
oxygen supply.   This combination leads to myocardial ischemia and infarction.  
Congestive heart failure also occurs with chronic pressure overload.  Often 
patients present with diastolic dysfunction, which eventually leads to systolic 
failure and cardiac congestion.  
Renal disease is an additional complication of hypertension.  
Hypertension-induced vascular lesions can also result in ischemia to the 
nephrons, or hyperperfusion of the glomerulus can damage the glomerular 
capillaries themselves.  Patients initially present with microalbuminuria, and 
pathology reveals glomerulosclerosis, which eventually leads to ischemic renal 
tubules.  The risk of end-stage renal disease (ESRD) is greater in hypertensive 
black patients than white patients, even when blood pressure is properly 
regulated.  Hypertension also increases the risk of ESRD in patients with diabetic 
nephropathy. 
Hypertension-induced damage to the vasculature is a common feature 
observed in many complications of the disease.  In addition to coronary artery 
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disease, stroke and renal disease, the damage to the vasculature of the eye or 
aorta can also have serious consequences.  Increased pressure in the aorta can 
cause a weakening of the vessel wall leading to the formation of an aneurysm.  
Most patients with aortic aneurysms are asymptomatic until the aneurysm 
ruptures.  This is a life-threatening event, and only 10-25 % of patients survive.  
The vasculature of the retina of the eye is also uniquely sensitive to damage.  
Chronic elevated pressure can result in narrowing of the arterioles with 
presentation of microaneurysm or macroaneurysm formation.  These 
hypertensive retinopathies can result in loss of vision. 
The regulation of blood pressure is vastly intricate and multifactorial.  
Many risk factors - both environmental and genetic - have been identified to 
increase BP including obesity, insulin resistance, high salt diet, aging, sedentary 
lifestyle, stress, and low potassium and calcium intake (13),(14).  On a whole 
body-level, many more factors can influence blood pressure regulation including 
neurogenic control, vascular reactivity, the renin-angiotensin system, sodium and 
water retention, nitric oxide, adrenal steroids and eicosanoids – including 
prostaglandins (PGs). 
 
Prostaglandins:  Biosynthesis and Catabolism 
 
Prostaglandins are biologically active lipid-derived autacoids generated by 
prostaglandin H synthase, commonly referred to as cyclooxygenase (COX).  The 
COX enzymes are the target of non-steroidal anti-inflammatory drugs (NSAIDs).  
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PGs are part of the family of eicosanoids which includes prostaglandins, 
prostacylins (PGIs), thromboxanes (TXs), and leukotrienes (LTs).  Eicosanoids 
are derived from the 20-carbon essential fatty acids arachidonic acid (AA), 
eicosapentaenoic acid (EPA), or dihomo-gamma-linolenic acid (DGLA).  
Specifically, PGs are derived from AA which is cleaved from the plasma 
membrane by phospholipase A2, the rate limiting step in PG biosynthesis.  COX 
catalyzes the oxidation of AA to PGG2 and reduction to PGH2.  The tissue-specific 
prostaglandin synthase enzymes then convert PGH2 into one of the five principal 
prostanoids – PGD2, PGE2, PGF2α, PGI2 and TXA2 (Figure 1.1). 
 Prostaglandins are ubiquitously produced and act in an autacrine or 
juxtacrine manner.  Their actions can be halted by efficient catabolic pathways.  
When PGE2 is administered intravenously, 95 % of PGE2 is inactivated within the 
first pass through the lungs.  This is achieved by β-oxidation, ω-oxidation by 
cytochrome P-450s, and PG-15-keto-reductase (15).  PGE2 is primarily 
inactivated by the conversion of the C-15 hydroxyl group into a ketone by NAD+ 
dependent 15-hydroxyprostaglandin dehydrogenase (16). 
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Figure 1.1 Biosynthesis of prostaglandins.  This figure illustrates the formation of 
the five principal prostanoids from arachidonic acid. 
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PGE2 Receptors: Pharmacological properties and signaling 
 
PGE2 mediates diverse and at times physiologically opposing effects, as is 
the case with regard to blood pressure regulation (17-19).  This unique feature 
can be explained in part by the existence of four PGE2 receptors, designated the 
E-Prostanoid (EP) receptors EP1 through EP4 which were cloned in the early 
1990s (20-23).  EP1-EP4 are G-protein coupled Family A receptors with seven 
transmembrane domains.  The EP1 and EP3 receptors are unique among PGE2 
receptors in that splice isoforms exist (24-27). The splice isoforms for the EP3 
receptor alter the C-terminal tail and each isoform has been shown to have 
similar binding properties but activate different signal transduction pathways.  
PGE2 binds with highest affinity to the EP3 and EP4 receptors (KD < 1 nM), and 
with lower affinity to the EP1 and EP2 receptors (KD > 10 nM)(28).  Even though 
each EP receptor binds the same endogenous ligand, the amino acid identity 
conserved across receptors is only 28-33 % (29).  Thus, selective compounds for 
the EP subtypes have been highly pursued.    
 
EP1 receptors 
The EP1 receptor was cloned in 1993 from a mouse lung cDNA library 
and later from human erythroleukemia cells (21,30). EP1 was first characterized 
based on its ability to induce smooth muscle constriction.  Signaling by the EP1 
receptor is primarily transduced by increasing intracellular calcium, most likely 
mediated by Gq family G-proteins (31).  However, it was reported that the calcium 
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flux weakly induces phosphoinositide turnover and generation of IP3 and the 
calcium flux is partially dependent on extracellular calcium, suggesting a non-Gq 
dependent pathway may also exist (24).  Additionally, the EP1 receptor has been 
demonstrated to couple to Gi/o –type G proteins, inducing the up-regulation of 
HIF-1α (32).   
An EP1 splice variant has been identified in rats (27).  The rEP1-variant 
mRNA was found to be highly expressed in the rat kidney, in a proportion roughly 
equal to that of rEP1.  This variant lacks the intracellular C-terminal tail of the 
receptor.  It is able to bind ligand similar to rEP1, but unable to transduce signals.  
When co-expressed in CHO-cells with rEP1 or rEP4, rEP1-variant significantly 
suppresses signaling through the rEP1 and rEP4 receptors, suggesting it may be 
physiologically relevant for attenuating the actions of PGE2 (27).  However, no 
splice variants have been identified in other species to date. 
Northern blot analysis of mouse EP1 mRNA demonstrated that the kidney 
has the highest expression of EP1, followed by lung, spleen and skeletal muscle, 
and low expression in the testes (21,30).  More recently, utilizing quantitative 
PCR analysis Regard et al. showed ubiquitous expression of EP1, present in all 
41 tissues tested, suggesting that EP1 is likely expressed in the vasculature (33).  
Unfortunately, due to the lack of well-characterized antibodies for EP receptors 
and the lower affinity of EP1 for PGE2, the only radiolabeled ligand available, 
protein distribution remains unknown. 
Selective agonists and antagonists have been essential for 
characterization of the individual EP receptor subtypes (Table 1.2).  17-phenyl-ω-
12 
 
trinor-PGE2 is the frequently utilized agonist with high affinity for mouse EP1 (pKi 
= 7.9) (34,35).  Sulprostone and partial agonist iloprost have the next highest 
affinities for mouse EP1 (pKi ≈ 7.7), but are less selective (34,36).  ONO-DI-004 
is by far the most selective agonist for EP1, but has lower affinity than other 
agonists (pKi = 6.8)(37).  AH6809 was frequently used in the past as an EP1 
antagonist, although its affinity for the mouse EP1 receptor is very poor, and 
much lower than its affinity for EP2.  ONO-8713, ONO-8711 and SC-51322 are 
currently used antagonists for EP1.  ONO-8713 is the most selective antagonist 
with a pKi of 9.5 at the mouse EP1 receptor (38).  ONO-8711 also has high 
affinity (pKi = 8.8) for mouse EP1, although it blocks EP3 receptor with 
reasonable affinity (pKi = 7.2) (39).  SC-51322 is by far the most commonly used 
antagonist due to its commercial availability, however, its pharmacological 
properties have only been reported in humans (pKi = 7.9) and not in mice (28).  
In humans, SC51322 is also reported to block the EP3 receptor (pKi = 6.2). 
 
EP2 receptors 
EP receptors were initially classified based on their function on smooth 
muscle (40).  The EP2 and EP4 receptors induce smooth muscle relaxation.  
Initially, there were two cloned receptor subtypes called EP2 (22,23).  Based on 
pharmacological selectivity, it was later shown that the first cloned EP2 receptor 
was actually EP4; the latter representing EP2. 
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Both EP2 and EP4 receptors couple to Gs-type G proteins which activate 
adenylate cyclase and increase intracellular cAMP ([cAMP]i) (22,23,41,42), 
however EP2 appears to increase [cAMP]i with greater efficacy than EP4 (43).  
Additionally, EP2 has also been demonstrated to couple to arrestin-mediated 
signaling pathways (44-46).  The EP2-beta-arrestin1-p-Src complex plays a 
significant role in the development and progression of skin cancer by activating 
EGFR (46).  Although EP2 has the least abundant mRNA expression of the EP 
receptors,  EP2 mRNA is expressed in the lung, bone marrow and ovary (33,47), 
however its expression is known to be altered in response to stimuli.  Therefore, 
mRNA quantitation in healthy mice may not portray an accurate picture of EP2 
expression in a disease setting. 
The EP2 receptor is classified due to its ability to be activated by the 
agonist butaprost.  In the mouse, butaprost, AH13205 and 11-deoxy-PGE1 all 
have similar affinity for the receptor (pKi = 6.6-7.3), although 11-deoxy-PGE1 also 
binds to the EP3 and EP4 receptors (34).  ONO-AE1-259 has improved potency 
over the previously named agonists (pKi = 8.5) and is highly selective for the EP2 
receptor in mice (37).  However, there is no reported data regarding its selectivity 
or affinity against human receptors.  Until recently, a quality EP2 antagonist did 
not exist.  AH6809 was shown to have moderate affinity for the EP2 receptor 
(mouse pKi = 6.5), however it also blocked the EP1 and DP receptors with high 
affinity in human tissue (28,34,48).  Recently, Pfizer reported development of a 
highly selective, potent EP2 receptor antagonist, PF-04418948 (49-51), which 
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should prove very useful for the study and validation of EP2 as a therapeutic 
target. 
EP3 receptors 
The EP3 receptor is known as the “inhibitory” PGE2 receptor and induces 
smooth muscle contraction.  EP3 primarily couples to a Gi-type family G proteins 
and inhibits adenylate cyclase and decreases [cAMP]i (20,41,52).  The EP3 
receptor has been demonstrated to increase intracellular calcium (52,53), and 
also to couple to G12-type G proteins, inducing the activation of RhoA (54).  EP3 
receptors are unique among the EP receptors in that several splice variants have 
been identified: at least 7 variants in humans, 5 in rabbits, 4 in rats, and 3 in mice 
(55-57).  The splice variants of EP3 have been demonstrated to alter constitutive 
activity, agonist-induced desensitization, trafficking, and signal transduction 
(26,58-60).  For example, of the three splice variants found in mice, alpha and 
beta isoforms couple to Gi G-protein, while the gamma isoform can couple to 
both Gi and Gs G-proteins (26). 
EP3 receptor expression is widespread, and it is found in the kidney, 
uterus, pancreas, stomach, thymus, spleen, smooth muscle of the 
gastrointestinal tract, vasculature, and CNS (33,61).  In the brain, EP3 receptor 
mRNA has been observed in the hippocampus, preoptic area, hypothalamus, 
locus coeruleus and raphe nuclei (62). 
Several selective agonists and antagonists exist for the EP3 receptor.  
The most commonly used agonist for EP3 is sulprostone, which has a pKi at 
mouse EP3 of 9.2 (34).  However, sulprostone is not entirely selective for EP3, 
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and has a pKi at mouse EP1 of 7.7.  Therefore interpretation of studies utilizing 
high concentrations must be carefully considered.  Sulprostone has a similar 
affinity for EP3 as M&B 28767 and SC-46275.  GR-63799 and ONO-AE-248 are 
more selective for mouse EP3 and have pKi’s of 8.7 and 8.1 respectively 
(34,37,63).  Multiple antagonists exist for the EP3 receptor as well, although not 
all have been characterized with mouse receptors.  ONO-AE3-240, L-798,106 
and DG041 have the highest affinities for the EP3 receptor and are selective for 
the human EP3 receptor (64-67).  ONO-8711 is also a selective antagonist with a 
pKi of 7.6.  Some of the effects of SC-51322, a commonly used antagonist for 
EP1, may be explained by the blockade of EP3 (pKi = 6.2), especially when high 
concentrations are used (28). 
 
EP4 receptors 
The EP4 receptor is an inducer of smooth muscle relaxation.  Initially, it 
was identified as the EP2 receptor but later determined to be the fourth subtype 
of EP receptors (22).  EP4 mRNA is predominantly localized the uterus, thymus, 
ileum, lung, spleen, adrenal gland, and kidney (33).  EP4 signals through Gs-type 
G protein, which activates adenylate cyclase and increases [cAMP]i.  The EP4 
receptor can also activate PI 3-kinase signaling pathways, leading to activation of 
extracellular signal-regulated kinases 1 and 2 (68).  The activation of PI-3K was 
demonstrated to be pertussis toxin (PTX) sensitive, and therefore mediated by Gi 
G-protein (69). PTX reduced PGE2 stimulated [cAMP]i in cells expressing EP4 
receptors, suggesting EP4-Gi signaling both inhibits adenylate cyclase and 
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activates PI-3K.  EP4 was also demonstrated to couple to arrestin-mediated 
signaling pathways (45,46).  
 EP4 was distinguished from EP2 due to its lack of activation in response 
to butaprost.  The EP4 receptor is preferentially activated by ONO-4819 (pKi = 
9.2) and ONO-AE-329 (pKi = 8.0), whereas these compounds’ affinities for the 
EP2 receptor are 100-1000 times lower (37,63,70).  In humans, 11-deoxy-PGE1 
is selective for EP4, however in mouse and rat 11-deoxy-PGE1 is able to bind 
EP2 and EP3 receptors in addition to EP4 (34,71,72).  In mice, 1-OH-PGE1 is a 
selective agonist but has lower affinity for EP4 (pKi = 6.7) (34).  In addition to 
agonists there are several antagonists available for blockade of the EP4 
receptor.  AH23848 was the most commonly used antagonist, however it has low 
affinity for EP4 (pKi = 5.3), and although selective against mouse receptors, has 
higher affinity for the human TXA2 receptor than human EP4 (28,71,73).  Among 
the newer antagonists, ONO-AE3-208 has the highest affinity for the mouse EP4 
receptor, although it also blocks the EP3 receptor at slightly higher 
concentrations despite being selective for the human EP4 receptor (74).  
Fortunately Merck compound MF-498 has both high affinity and selectivity for the 
EP4 receptor (75,76).  Additionally, GW627368 is selective and has reasonable 
affinity for EP4 (pKi = 7.1) (77).  These EP4 antagonists have proven to be 
particularly useful for the study of EP4 in disease given 95 % of EP4-/- mice die 
as a result of patent ductus arteriosis shortly after birth (78). 
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PGE2 receptors as therapeutic targets 
 
PGE2 mediates a wide range of physiological conditions including 
modulation of salt and water transport in the kidney, maintenance of blood 
pressure, preservation of the gastric mucosa, tumor growth and angiogenesis, 
and modulation of immune responses.  The COX/PGE2 pathway has long been a 
target of therapeutic benefit.  Some of the most commonly used over-the-counter 
medications - NSAIDs - block this pathway by inhibiting the COX enzymes.  
These drugs are very valuable for the treatment of pain, inflammation, and fever; 
however chronic use can cause serious side effects including ulcers and 
gastrointestinal bleeding, hypertension, heart attack or stroke.  In an effort to 
eliminate the side effects, subtype selective inhibition of COX-2, while 
maintaining the function of the “housekeeping” isoform COX-1, was pursued.  
The drugs produced include rofecoxib (Vioxx) and celecoxib (Celebrex).  
Unfortunately, rofecoxib was withdrawn from the market due to an increased risk 
of myocardial infarction and stroke, despite showing efficacy against cancer 
progression and reduced incidence of gastrointestinal bleeding.  These 
unexpected side effects were a result of an imbalance in thromboxane and 
prostacylin action.  Celecoxib has remained on the market and is currently 
prescribed for rheumatoid and osteoarthritis, acute pain and familial 
adenomatous polyposis.   
Attention has since focused on alternate ways to modulate the COX/PGE2 
pathway.  These include targeting the catabolic enzyme for PGE2, prostaglandin 
dehydrogenase, targeting the synthases responsible for production of the PGE2, 
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targeting the transporter which moves the intracellular PGE2 across the plasma 
membrane, or targeting the PGE2 receptors themselves.  Therefore, selective 
agents and knockout mice have been used to investigate the subtype specific 
roles of the EP receptors in health and disease. 
 
EP1 receptors 
Although EP1-/- mice have no gross dysfunctions, they have been used to 
support the role of EP1 in impulse activity, pain, hypertension, urine 
concentration and cancer.  Most notably, the EP1 receptor is actively being 
pursued as a therapeutic for pain.  In two acute pain models, EP1-/- mice have 
been shown to have reduced nociceptive responses (79).  The reduction in pain 
phenocopied the effect observed by treatment with a COX-2 inhibitor, suggesting 
the EP1 receptor is the major mediator of COX/PGE2 pain (79).  PGE2-
dependent mechanical allodynia, or enhanced sensitivity to a stimulus which 
normally does not cause pain, is prevented in EP1-/- mice (80).  Furthermore, 
anti-nociceptive and anti-inflammatory responses have been observed as a result 
of administration of an EP1 antagonist in several studies (67,81-84). 
EP1-/- mice exhibit modestly reduced systolic blood pressure (79).  This 
effect was also observed in a setting of hypertension.  EP1-/- mice have a 
blunted response to acute and chronic angiotensin II-dependent hypertension 
(85).  Additionally, EP1 antagonists significantly reduced hypertension in diabetic 
mice and spontaneously hypertensive rats (85,86).  EP1 antagonists have also 
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been used for the prevention of hypertensive renal damage and diabetic 
nephropathy (87,88).    
In the lung, EP1 receptors constrict the airway of mice and mediate 
surfactant secretion from rat alveolar cells (89,90).  In the stomach, EP1 plays 
both beneficial and harmful roles. EP1 enhances histamine-induced gastric injury 
while also conferring cytoprotection against hemorrhagic lesions and is essential 
for HCO3
- secretion (91-94).  EP1 receptors have also been shown to play a 
critical role in carcinogenesis.  EP1-/- mice have reduced aberrant crypt foci and 
tumor formation in the azoxymathane colon cancer model (39,95).  EP1 
antagonist ONO-8711 was demonstrated to reduced tumor burden in a model of 
breast cancer (96).  Therefore, EP1 antagonists may be of therapeutic 
importance for pain, hypertension, and cancer.   
There are few indications when EP1 agonism would be beneficial.  EP1-/- 
mice exhibit behavioral deficits including impaired social interaction, aggression, 
diminished cliff avoidance and exaggerated acoustic startle response (97).  
Therefore, agonism of EP1 receptors could prove to be useful for control of 
impulsive behavior, although major unwanted side effects would be expected. 
 
EP2 receptors 
EP2 has been demonstrated to be involved in asthma, blood pressure 
homeostasis, uterine contraction, fertility, maintenance of bone, and cancer.  EP2 
is generally considered to have anti-inflammatory roles (98).  EP2-/- mice have 
reduced fertility (17,78,99).  Although female EP2-/- mice are able to become 
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pregnant, there is a reduction in litter size.  This is a result of reduced fertilization 
of the oocyte due to incomplete expansion of the cumulus cells required for 
oocyte maturation (78,99,100).  The EP2 receptor mediates the vasodilator 
responses of PGE2 (101).  During high salt intake, deletion of EP2 results in salt-
sensitive hypertension (17,99).  One mechanism by which EP2 can modulate 
blood pressure is through PGE2-induced renin release.  EP2 and EP4 activate 
renin exocytosis at the juxtaglomerular cell, eventually resulting in 
vasoconstriction of the afferent arteriole (102-104).  EP2 also mediates sodium 
excretion, suggesting that in a high salt setting EP2 stimulates natriuresis and 
maintenance of normal blood pressure (105). 
The EP2 receptor mediates the PGE2 bronchodilator response, 
suggesting agonism of EP2 may be beneficial for the treatment of asthma.  This 
has been demonstrated in both human and mouse (89,106-108).  Agonism of 
EP2 receptors could prove to be more beneficial than commonly used treatments 
which relieve bronchospasm, because EP2 receptors also inhibit lung mast cell 
degranulation (109).  AH13205 was tested clinically with no success, however it 
should be noted that the potency to this EP2 agonist is weak, and there may be 
great benefit from a more potent compound if it becomes available (110). 
The EP2 receptor can positively and negatively contribute to cancer.  In 
skin cancer, overexpression of EP2 enhances chemically induced skin cancer 
and EP2-/- mice are resistant to the cancer (111,112). In intestinal and prostate 
cancers, EP2 receptors contribute to endothelial cell motility and mediate 
angiogenesis (113).  In mammary cancer, EP2 deficiency reduces tumor growth, 
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angiogenesis, and metastasis, while over expression of EP2 enhances tumor 
burden (114).  This supports a pro-tumor role of EP2.  In contrast, loss of EP2 
receptors in keratinocytes has been suggested as a mechanism for neoplastic 
progression by increasing invasiveness.   Furthermore, EP2 receptors are 
protective in UV-induced carcinogenesis (115,116), supporting an anti-tumor role 
of EP2.  It is essential to appreciate the complexity of the EP2 receptor in cancer 
progression.  Therapeutic manipulation of EP2 for the treatment of cancer would 
require determining whether EP2 is acting in a pro- or anti-tumorigenic fashion 
prior to treatment. 
 
EP3 receptors 
EP3 receptors have been implicated in many physiologic events including 
fever, pain, platelet aggregation, myocardial infarction, bladder hyperactivity, 
cancer, obesity, and Alzheimer’s disease.  Upon gross observation, EP3-/- mice 
appear to be normal (117,118).  However, EP3-/- mice have been shown to have 
an impaired febrile response (118), suggesting EP3 antagonists could be 
effective antipyretic agents.  Analgesic effects are also produced by EP3 
antagonists, or the use of EP3-/- mice, in a model of acute herpetic pain (119).  
EP3 antagonism has been clinically pursued for treatment of thrombotic 
disorders.  PGE2 inhibits platetet aggregation at high dose, but also can 
potentiate other proaggregatory agents (120).  EP3 receptors have been 
demonstrated to mediate this proaggretory effect (64,121-124).  Furthermore, 
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EP3-/- mice have increased bleeding and reduced susceptibility to 
thromboembolism (123).   
With the use of EP3 antagonists, the receptor has been identified as a 
target for treatment of bladder hyperactivity disorders.  Treatment with DG041 
inhibited responses to bladder distension and reduced bladder motility (125).  
Furthermore, EP3-/- mice have been reported to have increased bladder 
capacity, while infusion of an EP3 agonist reduces bladder capacity in wildtype 
mice (126). 
EP3 has also been implicated in metabolic regulation.  EP3-/- mice had 
increased frequency of feeding during the light cycle and became obese on a 
normal fat diet (127).  Increased leptin and insulin levels were also observed with 
the obesity (127).  In a model of subacute neuroinflammation, deletion of EP3 
reduced pro-inflammatory gene expression, cytokine production, oxidative stress, 
and reversed the decline in presynaptic proteins, suggesting a possible role for 
EP3 in Alzheimer’s disease (128,129). 
Similar to the EP2 receptor, in cancer EP3 can have both pro- and anti-
tumorigenic effects.  In human colon cancer EP3 mRNA expression is reduced.  
Agonism of EP3 in a colon cancer cell line reduced cell viability, supporting the 
theory that downregulation of EP3 allows for enhanced colon carcinogenesis 
(130). Overexpression of individual splice variants decreased tumorigenic 
potential in cell lines and reduced tumor burden in vivo (54).  EP3-/- mice also 
exhibited reduced tumor burden and angiogenesis in an implanted tumor model 
(65).  Similar reductions in tumor burden were observed upon treatment with an 
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EP3 antagonist (65).  In contrast, EP3 decreases aromatase activity, suggesting 
a possible inhibitory role in breast cancer (131). 
 
EP4 receptors 
EP4 receptors have been proposed to mediate vasodepression, closure of 
the ductus arteriosus, renin secretion,bone homeostasis and intestinal 
homeostasis.  EP4-/- mice have been demonstrated to have persistent patent 
ductus arteriosus, and most mice die within 3 days of birth due to pulmonary 
congestion and congestive heart failure (132,133).  The ductus arteriosus is the 
fetal shunt between the pulmonary artery and aorta, and its closure at birth is 
essential.  Indomethacin can be given late in pregnancy to induce closure of the 
ductus in wildtype, but not EP4-/- mice (132).   
EP2 and EP4 receptors have also been shown to mediate PGE2 
stimulated renin secretion.  PGE2 is a well established stimulator of renin 
(19,134).  It is also known that PGE2 is produced locally at the macula densa in 
response to relevant concentrations of NaCl (20-40 mM) (135).  Using isolated, 
perfused kidneys for EP1, EP2, EP3 and EP4 knockout mice, it was 
demonstrated that EP4 stimulates renin secretion at low PGE2 concentrations, 
regulating basal activity, while both EP4 and EP2 stimulate renin at higher 
concentrations of PGE2 (102).  However, EP receptors do not appear to mediate 
COX-2 dependent production of renin at the macula densa in low-NaCl settings, 
since no differences in renin secretion were observed between genotypes when 
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loop diuretics, which impair the ability of the macula densa to sense NaCl, were 
administered (102). 
EP4 is the primary PGE2 receptor supporting bone maintenance, and is 
able to mediate both bone formation and bone reabsorption.  EP4-/- mice have 
been shown to have reduced bone mass and an inability to properly repair 
fracture damage (136).  Despite having similarly sized bones, EP4-/- mice had 
reduced structural and apparent material strength in the femur and vertebrae 
compared to wildtype mice (137).  Administration of an EP4 agonist has been 
shown to restore bone mass and strength in ovariectomized or immobilized rats, 
suggesting activation of EP4 could be of great therapeutic benefit for conditions 
with reduced bone mass (70). 
It has been established that treatment with NSAIDs can trigger or worsen 
inflammatory bowel diseases.  This phenomenon is due to reduced activation of 
EP4. In a dextran sodium sulfate–induced colitis, disruption of EP4 and not EP1, 
EP2, EP3, FP, TP or IP resulted in enhanced colitis in wildtype mice (74). 
Administration of an EP4 antagonist to wildtype mice was able to mimic this 
effect, while treatment with an EP4 agonist ameliorated severe colitis (74).  The 
anti-inflammatory EP4 receptor was critical to mucosal barrier function and 
maintenance of epithelial cells, and suggests EP4 agonism may be of therapeutic 
value for treatment of inflammatory bowel diseases such as Crohn disease and 
ulcerative colitis. 
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PGE2 receptors in blood pressure regulation 
 
PGE2 is a major prostanoid contributing to the regulation of blood 
pressure, where it can exert either vasopressor or vasodepressor effects 
depending upon the setting (17-19).  Previous studies have determined that the 
EP1 and EP3 receptors primarily mediate the pressor response, while the EP2 
and EP4 receptors mediate the depressor response (17,85,99,134,138-
140)(Figure 1.2).  
The role of PGs in the regulation of blood pressure is highlighted by the pro-
hypertensive action of non-steroidal anti-inflammatory drugs (NSAIDs) which 
inhibit cyclooxygenase mediated prostanoid production, suggesting that 
prostaglandins have an anti-hypertensive role (141,142).  However, under certain 
conditions NSAIDs can also have hypotensive effects supporting a 
prohypertensive role for PGs (143).  Of note, PGE2 is a well established 
stimulator of renin (19,102,135,144). Experiments in conscious dogs 
demonstrated that intrarenal infusion of PGE2 results in a sustained rise in mean 
arterial pressure, which highly correlates with plasma renin activity (19).  This 
suggests the rise in blood pressure was related to the increased renin activity.  
Futhermore, 20 – 40 mM NaCl concentrations have to shown to induce local 
PGE2 production in the macula densa (135).  Overall, the balance of functionally 
antagonistic prostaglandin action fine-tunes blood pressure homeostasis.   
Isomerization of PGH2 to PGE2 by microsomal PGE synthase (mPGES) 
plays a key role in the maintenance of blood pressure homeostasis by regulating 
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vascular tone, sodium balance and/or renin release (145).  Inhibitors of mPGES 
are currently being pursued for treatment of cancer, pain and inflammation; 
however, unwanted pro-hypertensive effects may result from this strategy.  In 
rodents, deletion of mPGES-1 has been shown to further increase blood 
pressure in several models of hypertension, including deoxycorticosterone-salt 
water-induced hypertension and acute or chronic treatment with angiotensin II 
(146-148).  In humans, where there is a great deal of phenotypic heterogeneity, 
the contribution of PGE2 towards hypertension is more controversial.  In some 
cases, patients with essential hypertension have been shown to have low urinary 
excretion of PGE2; however, in other cases patients have been shown to have 
high urinary PGE2 excretion (149).  This inter-patient variability may result in a 
wide range of untoward side effects for mPGES inhibitors.  In order to gain a 
better understanding of the effects of PGE2 on blood pressure homeostasis, 
attention has been focused on the actions of its receptors using knockout mouse 
models. 
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Figure 1.2 PGE2 receptors in blood pressure regulation.  Upon PGE2-induced 
activation EP2 and EP4 function as vasodepressor receptors and EP3 and EP1 
function as vasopressor receptors 
 
Vasodepressor Receptors 
Upon acute infusion, PGE2 is a vasodepressor in both humans and mice 
(17,138,150). This observation underscores the pro-hypertensive effects of 
blockade of all prostaglandin production and subsequent receptor activation by 
NSAIDs (141,151-154), which is consistent with the loss of a tonic vasodepressor 
PG effect. It has been shown that this depressor effect is primarily due to the 
activation of the EP2 receptor; however, when the EP2 receptor is deleted, the 
loss of the depressor response unmasks a PGE2 pressor response (17). 
Moreover, EP2-/- mice fed a high-salt diet experienced an increase in blood 
pressure consistent with a protective role for EP2 activation in salt-sensitive 
hypertension (17).  Intravenous infusion of the EP2 agonist ONO-AE1-259 into 
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Wistar rats increases retinal arteriolar and venous diameter and substantially 
reduces mean arterial pressure (155).  EP2 and EP4 receptors evoke an 
increase in [cAMP]i through a Gs coupled pathway, a classical mechanism for 
smooth muscle relaxation. Hristovska et al. demonstrated a dose-dependent 
relaxation in response to PGE2 in aortic rings which was lost in tissue from EP4-/- 
mice but remained intact in EP2 -/- tissue.  The EP4 dilator effect was dependent 
upon endothelium-derived nitric oxide production via eNOS (156).  Acute blood 
pressure studies are challenging in EP4 -/- mice because the mice exhibit near 
complete perinatal lethality in inbred strains as a result of persistent patent 
ductus arteriosus (132).  Analysis of studies performed with surviving EP4-/- 
animals on a mixed-strain background may not be straightforward as their 
survival may be dependent on modifier genes.  Nonetheless, deletion of EP4 
resulted in a diminished vasodepressor response to PGE2 (138). In rats, infusion 
of the EP4 selective agonist ONO-AE1-329 significantly reduces blood pressure; 
it does not alter retinal vessel diameter (155).  Taken together is consistent with 
EP4 vasodilator action in a subset of vascular beds. 
 
Vasopressor Receptors 
As described above, the pressor effects of systemic PGE2 infusion are 
only observed in the absence of the predominant depressor receptor EP2 (17).  
In contrast, infusion of EP3 receptor selective agonists such as sulprostone, 
M&B28767 or SC46275 in wildtype mice results in an acute and substantial rise 
in mean arterial pressure (139).  The EP3 mediated pressor effect undergoes 
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desensitization with repeated administration of EP3 agonists. In EP2-/- mice after 
desensitization of EP3 responses, the depressor action of EP4 in response to 
PGE2 infusion is then apparent (139).  Thus, upon systemic infusion of PGE2 in 
mice the depressor action of EP2 predominates, followed by the pressor action of 
EP3, and then the depressor action of EP4.  Importantly, the order of expression 
of EP receptor mRNA does not mirror the phenotypic effects of the EP receptors.  
RNA levels determined by RNAse protection identified expression levels of 
EP3>>EP4>EP1≥EP2 in both renal resistance vessels and the aorta (139).  It is 
unclear whether changes in EP receptor density underlie changes in vascular 
tone in the hypertensive state.  Because messenger RNA levels do not correlate 
with receptor function, and anti-receptor antibodies are of questionable value, 
this remains an important unanswered question. 
In contrast to the depressor effects of systemic administration, when PGE2 
is administered intracerebroventricularly (ICV) a rise in mean arterial pressure 
occurs, accompanied with tachycardia and enhanced renal sympathetic nerve 
activity (157).  These effects were ascribed to the EP3 receptor using ICV 
infusion of subtype selective EP receptor agonists (157).  Taken together, these 
data demonstrate that the centrally mediated pressor actions of PGE2 are EP3-
mediated.   
Although the EP1 receptor does not appear to play a significant role in the 
blood pressure effects of systemically administered PGE2, it has been shown to 
be a significant contributor to hypertension, particularly in cases with enhanced 
renin-angiotensin system activity.  Genetic deletion of the EP1 receptor in mice 
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has been shown to significantly decrease systolic blood pressure, an effect 
amplified when mice are fed a low sodium diet (79).  Importantly, EP1-/- mice 
have blunted pressor responses to both acute and chronic angiotensin II 
administration (85).  In isolated vascular preparations of preglomerular arterioles 
and mesenteric arteries, pre-treatment with SC51322, an EP1/3 antagonist, was 
able to abolish any angiotensin II-mediated vasoconstriction (85).  Furthermore, 
treatment of spontaneously hypertensive rats, a multifactorial model of essential 
hypertension, with SC51322 significantly reduces blood pressure (85), indicating 
the EP1 receptor and/or EP3 receptor may be novel targets for the treatment of 
hypertension.   
 
 
PGE2 and the consequences of hypertension 
Hypertension is an established risk factor for cardiovascular diseases 
including stroke, myocardial infarction, heart failure, arterial aneurysm and is the 
leading cause of chronic kidney failure.  Current anti-hypertensive therapies 
reduce the risk of the related cardiovascular sequelae, though not to baseline risk 
observed in normotensive subjects. There is an unmet need for treatment which 
will reduce blood pressure and maximize target organ protection (158).  In 
considering whether PGE2 and its receptors make viable drug targets for 
hypertension, determination of their ability to reduce end-organ damage will be 
important.  It has been shown that genetic deletion of mPGES-1 in mice results in 
increased blood pressure (146-148).  Despite this, deletion of mPGES-1 has also 
32 
 
been shown to protect against aortic aneurysm formation and vascular injury 
(159,160).  Angiotensin II infusion into hyperlipidemic mice produced fewer and 
less severe aneurysms, and reduced oxidative stress on a mPGES-1-/- 
background compared to wildtype mice (160).  However, these results were 
complicated by the observed increase in PGI2 and PGD2 production 
accompanying the reduction in PGE2 (160).  It is yet to be determined whether 
potentially beneficial substrate diversion is a consequence specific to genetic 
mPGES-1 deletion, or would be recapitulated with chronic use of an mPGES 
inhibitor.   
Blockade of individual PGE2 receptors might result in a reduction in end-
organ damage while being less likely to produce unwanted side effects.  In 
addition, GPCRs are demonstrably “druggable” and are one of the most common 
targets of currently developed therapeutic agents.  Antagonism of EP1 receptors 
has been shown to preserve renal function, and reduce tubulointerstitial damage, 
proliferative lesions, fibrotic area and proteinuria in stroke-prone spontaneously 
hypertensive rats (87), as well as cerebrovascular dysfunction induced by 
angiotensin II (161).   In the study performed in stroke-prone hypertensive rats, 
tail cuff blood pressure was modestly reduced two weeks post-treatment with an 
EP1 antagonist, but this reduction was not maintained past five weeks of 
treatment. Nonetheless treatment with the EP1 antagonist provided end-organ 
protection.  In contrast to the deleterious actions of the EP1 receptor, EP2 and 
EP4 receptors have been shown to be cardioprotective; it would seem important 
to maintain function of these receptors.  For example, deletion of the EP4 
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receptor in a mouse model of ischemia reperfusion of the heart significantly 
increased infarct size, while treatment of wildtype mice with an EP4 agonist, 
4819-CD, reduced infarct size (162).  Therefore, EP4 agonists could be useful for 
reducing blood pressure and afford cardioprotective benefits. Selective blockade 
of EP1 and/or EP3 receptors, while EP2 and EP4 signaling remains intact may 
be preferable to the loss of signaling in all four receptors resulting from inhibition 
of PGE2 ligand production. 
PGE2 plays a dynamic role in regulation of blood pressure homeostasis.  
The existence of multiple receptors with diverse signaling abilities allows for 
modulation both positively and negatively.  The development and availability of 
additional highly selective agonists and antagonists for EP receptors is 
fundamental to the advancement of the field.  Unwanted side effects resulting 
from inhibition of the cyclooxygenase enzymes upstream of prostanoid 
production demonstrated the value of selective targeting as proximal to the 
pathophysiological action as possible.   Development of new therapeutics 
targeting specific PGE2 receptors could reduce blood pressure and provide end-
organ protection, while minimizing side effects. 
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Objective 
 
As summarized above, PGE2 and its receptors mediate a wide range of 
physiologic processes.  With regards to blood pressure regulation, PGE2 can act 
in a pro-hypertensive or anti-hypertensive manner.  While it has been 
demonstrated that EP2 and EP4 receptors mediate the vasodepressor actions of 
PGE2 and the EP1 and EP3 receptors mediate the vasopressor actions, the role 
of the EP receptors in modulating downstream end-organ damage in 
incompletely characterized.  Current therapies for cardiovascular and renal 
complications associated with hypertension and diabetes are largely focused on 
reduction of mean arterial pressure.  However, pharmacologic reduction of blood 
pressure in patients with hypertension – even to the same blood pressure as 
normotensive individuals – does not reduce the risk of CVD and renal events to 
an incidence similar to that of normotensive individuals.  This highlights the need 
for development of novel therapeutic agents which will not only lower blood 
pressure but also reduce end-organ damage.  
Drugs which block the renin-angiotensin-aldosterone pathway are 
considered superior to other anti-hypertensive treatments due to their beneficial 
actions directly on the kidney.  Furthermore, PGE2 and the EP1 receptor have 
been demonstrated to mediate at least part of the actions of angiotensin II.  
Therefore, I sought to determine the role of the vasopressor PGE2 receptors in 
the development of hypertensive end-organ damage.  Specifically, I sought to 
address the following questions:  What are the consequences of genetic 
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disruption of EP1 or EP3 receptors in development of Ang II- mediated 
hypertension?  Do EP1 or EP3 receptors contribute to end-organ damage in a 
setting of hypertension of diabetes?  Are beneficial effects on end-organ damage 
dependent of blood pressure reduction?  Does the EP1 receptor contribute to 
Ang II independent hypertension?  This thesis describes studies utilizing EP1 
and EP3 receptor knockout mice which are designed to answer these questions 
and advance our knowledge of the role of EP receptors in settings of disease. 
 
  
36 
 
CHAPTER II 
 
DISRUPTION OF EP1 ATTENUATES END-ORGAN DAMAGE IN A MOUSE 
MODEL OF HYPERTENSION 
 
Introduction 
 
Hypertension is a major risk factor for cardiovascular diseases (CVD), 
increasing the risk of stroke, myocardial infarction, arterial aneurysms, and heart 
failure.  Approximately 30 % of adults in the US have hypertension and the 
incidence of CVD remains greater in hypertensive patients than normotensive 
patients, highlighting the need for novel therapeutic agents (158).   
PGE2 is a major prostanoid found in the mouse kidney and vasculature 
contributing to the regulation of blood pressure, where it can exert either 
vasopressor or vasodepressor effects (17-19).  Four PGE2 receptors (EP1 
through EP4) mediate these effects with the EP1 and EP3 receptors primarily 
mediating the pressor response of PGE2, while the EP2 and EP4 receptors 
mediate the depressor response (17,85,99,134,138-140). 
Each PGE2 receptor has distinct tissue localization and elicits 
characteristic signal transduction pathways (61).  EP1 couples to Gq-proteins, 
resulting in mobilization of intracellular calcium, and stimulation of 
phosphoinositide turnover activating protein kinase C.  The EP2 and EP4 
receptors couple to Gs-proteins, which increase intracellular cAMP.  The EP3 
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receptor couples to Gi-proteins, decreasing intracellular cAMP (For reviews, see 
(29,61)).  Receptors couple to alternative signal transduction pathways as well, 
including arrestin-mediated signaling pathways (45,46).  
Systemic infusion of PGE2 results in a vasodepressor response 
(17,138,150), primarily through EP2 activation.  In the absence of EP2, a PGE2 
pressor response is unmasked (17), mediated by the EP3 receptor (139).  
Agonist induced EP3 tachyphylaxis in the background of EP2 -/- mice uncovers a 
depressor action of EP4 (139).  EP1 does not appear to play a significant role in 
the blood pressure effects of systemically administered PGE2, however, it does 
contribute to hypertension.  Genetic disruption of the EP1 receptor in mice has 
been shown to decrease blood pressure, particularly when mice are fed a low 
sodium diet (79).  Furthermore, EP1-/- mice have blunted pressor responses to 
both acute and chronic angiotensin II (Ang II) administration (85).  In isolated 
vessel preparations, pre-treatment with the EP1 selective antagonist SC51322 
reduced Ang II mediated vasoconstriction (85).  Treatment of spontaneously 
hypertensive rats with SC51322 significantly reduces blood pressure (85), 
indicating blockade of the EP1 receptor may be a target for the treatment of 
hypertension. 
EP1 blockade has been shown to positively affect renal function in stroke-
prone spontaneously hypertensive rats (87), as well as cerebrovascular 
dysfunction induced by Ang II (161), implicating the EP1 receptor in hypertension 
and resultant end-organ damage.  This has yet to be investigated in detail and in 
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the context of other organ damage.  Therefore, EP1+/+ and EP1-/- mice were 
studied in a model of severe hypertension. 
 
Experimental Procedures 
 
Animal procedures 
The hypertension model was carried out as described by Kirchhoff and co-
workers (163).  Ten-to-16 week old male C57BL/6J (EP1+/+, Jackson Labs, 
USA) and EP1-/- mice (85) backcrossed at least ten generations onto C57BL/6J 
were uninephrectomized (Nphx) under ketamine/xylazine (100 mg/kg and 15 
mg/kg) anesthesia.  Two weeks later, a subcutaneous 50 mg 
deoxycorticosterone acetate (DOCA) pellet (Innovative Research of America, 
USA) was implanted and drinking water supplemented with 1 % NaCl. After an 
additional week, a subcutaneous osmotic mini-pump was implanted (Alzet model 
1002; Durect Corporation, USA) delivering 1.5 ng angiotensin II (Calbiochem, 
USA) per minute per gram body weight. Mice were followed for two more weeks 
when tissues were collected for histology.   Additional studies eliminating one of 
the three elements from the protocol were performed, while keeping the time 
frame between surgeries consistent. Animals were maintained in an AAALAC 
accredited rodent facility in individually ventilated microisolator cages on a 12:12 
light dark cycle.  All procedures were done in accordance with the policies of the 
Institutional Animal Care and Use Committee at Vanderbilt University. 
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Examination of aortic aneurysm and dissection  
Upon necropsy aortic aneurysms and dissections were observed in both the 
thoracic and abdominal aorta, and severity was scored visually using the 
following scale adapted from Manning et al., 2002 (164).  Type 0: no aneurysm, 
Type 1: dilated aorta with no thrombus, Type 2: remodeled tissue that frequently 
contains thrombus, Type 3: a pronounced bulbous form of type 2, Type 4: 
multiple overlapping aneurysms, or a dissection extending the length of the aorta, 
Type 5: ruptured aorta.  Hematoxylin and eosin (H/E) and Masson’s Trichrome 
stains was used on formalin-fixed, paraffin-embedded aorta sections.  
Immunohistochemistry was performed for macrophage (CD11b and F4/80, 
Novus Biologicals cat# NB600-1327 and NB600-404), neutrophils 
(myeloperoxidase, Dako cat# A0398), T-cells (CD3, Santa Cruz cat# sc-1127), 
and B-cells (CD45R/B220, BD Pharmigen cat# 553084).  Inflammation, collagen 
organization and all immunohistochemistry sections were scored at the site of the 
lesion in a blinded fashion by a comparative veterinary pathologist. 
 
Fraction water weight determination 
Fractional water weight was determined as previously described (165).  Eight 
EP1+/+ and seven EP1-/- mice were sacrificed 5 days post-Ang II administration, 
their carcasses weighed (wet weight) and incubated at 60°C.  Body weight was 
measured daily until it remained unchanged for 3 days, indicating dry body 
weight.  Fractional water weight was determined using the equation:  Fractional 
water weight = 1 - (dry weight/wet weight).   
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Determination of urinary albumin/creatinine ratios 
Albumin/Creatinine ratios (ACR; expressed as mg albumin/mg creatinine) were 
measured from 20-200 μL volumes of spot urine using Albuwell M ELISA kit, and 
urinary creatinine was measured using the Creatinine Companion (Exocell, 
Philadelphia, USA).   
 
Determination of Blood Urea Nitrogen levels 
To assess the renal function, blood urea nitrogen (BUN) was determined using 
an iSTAT-1 analyzer (Abbott Point of Care Inc., New Jersey, USA).   Whole 
blood was obtained from saphenous vein and immediately assayed utilizing 
Chem8+ cartridges. 
 
Assessment of Renal Histopathology 
Tissues were fixed overnight in 10 % neutral buffered formalin. Kidneys were 
processed routinely, embedded in paraffin, sectioned at 5 microns, stained with 
H/E or Masson’s Trichrome and evaluated by light microscopy. 
 
Quantitative PCR 
Total RNA from kidneys and aortae was isolated using the TRIzol reagent 
followed by RNA cleanup with a Qiagen RNeasy kit.  cDNA was made using the 
high-capacity cDNA archive kit (Applied Biosystems).  Quantitative PCR was 
performed using Applied Biosystems 7900HT Fast Real-time PCR system with 
Taqman gene expression assays for Ngal (Mm01324470_m1), Kim-1 
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(Mm00506686_m1), Cyclooxygenase-2 (COX-2) (Mm00478374_m1), and 18S 
rRNA (4319413E).  Fold difference in mRNA expression is plotted relative to a 
normal EP1+/+ kidney sample. 
 
Echocardiography 
Transthoracic echocardiography was performed on lightly-anesthetized 
(isoflurane) mice using the VisualSonics VEVO2100 system (30 MHz 
transducer).  Left ventricular posterior wall dimensions (LVPW), intraventricular 
septum dimensions (IVS), left ventricular interior diameter (LVID), fractional 
shortening (FS) and ejection fraction (EF) were measured for analysis of cardiac 
structure and function at baseline, prior to uninephrectomy, and five days post-
Ang II administration. 
 
Intracarotid blood pressure measurement 
Intracarotid blood pressure was measured under ketamine (25 mg/kg) and 
inactin (100 mg/kg) anesthesia delivered intraperitoneally.  Mice were placed on 
a thermal pad and a PE-10 catheter was inserted into the left carotid artery.  The 
catheter was connected to a TXD-310 transducer and blood pressure was 
measured using a Digi-Med BPA 400 (Micromed).  Mice were equilibrated 30-60 
minutes until stable values were attained.  Ten minute blood pressure 
measurements were collected and average mean arterial pressure (MAP) is 
plotted. 
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Antihypertensive Treatment 
Blood pressure reduction was achieved by adding hydralazine (200 mg/L) to the 
1 % NaCl drinking water beginning three days prior to angiotensin II mini-pump 
implantation.  Treatment was continued for the duration of the experiment, or a 
total of 17 days. 
 
Statistical Analysis 
Data are means ± SEM, using GraphPad Prism software (GraphPad Software 
Inc., USA). Analysis utilized Student’s t test and Fisher’s exact test. Kaplan Meier 
survival curves were evaluated with the Log-rank (Mantel-COX) test. P < 0.05 
was considered statistically significant for all studies. 
 
Results 
 
EP1-/- mice were protected against Nphx/DOCA-NaCl/Ang II mortality 
We employed a model of severe hypertension to investigate the contribution of 
the EP1 receptor in hypertensive end-organ damage (163).  Unexpected 
mortality was observed following implantation of the Ang II osmotic pump (Figure 
2.1A).  Of 58 EP1+/+ mice, 60 % died within 14 days.  EP1-/- mice were 
significantly protected against mortality; of 35 EP1-/- mice only 24 % died (P = 
0.0044).  Modified protocols omitting one of the three components (Nphx, DOCA-
NaCl, or Ang II) demonstrated all components of the model played an essential 
role in causing mortality (Figure 2.1B, Nphx/DOCA-NaCl/Ang II vs. Nphx/DOCA-
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NaCl, Nphx/Ang II or DOCA-NaCl/Ang II, N = 10 per group, P = 0.011, < 0.005, 
or < 0.005 respectively).  
 
EP1-/- mice had reduced aortic aneurysm rupture, but comparable aortic 
histopathology 
Post-mortem analysis of EP1+/+ and EP1-/- mice in the full model indicated a 
significant portion of the mice died as a result of rupture of the aorta.  Aneurysms 
and dissections were observed in both the thoracic and abdominal aorta.  37 % 
of EP1+/+ and 13 % of EP1-/- mice died due to aortic rupture. Aortic aneurysms 
were present in 67 % of EP1+/+ mice and 40 % of EP1-/- mice.  Aneurysm 
severity was scored at death on a scale of 0-5 (Figure 2.2A).  A reduction in 
aneurysm severity was observed in EP1-/- mice compared to EP1+/+ mice 
(Figure 2.2B, P = 0.049).  H/E staining revealed aneurysms and dissections in 
the wall of the thoracic and abdominal aorta were accompanied by inflammation 
in both EP1+/+ and EP1-/- mice (Figure 2.3A-E, P = 0.3975).  Analysis of aortic 
sections from both thoracic and abdominal lesions of each genotype 
demonstrated macrophage and neutrophils were most abundant, with no 
differences observed between the genotypes in any immune cell component 
(Figure 2.3F).  COX-2 has been shown to play a significant role in aortic 
aneurysm formation and macrophage infiltration (166,167).  COX-2 mRNA was 
elevated in abdominal aortae 2-5 days post Ang II administration, though 
differences between genotypes were not observed (Figure 2.3G, P = 0.774).  
Aortic sections stained with Masson’s Trichrome showed that regardless of 
genotype there was less fibrillar collagen present in vessels that ruptured, and 
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Figure 2.1.  Nphx/DOCA-NaCl/Ang II induced substantial mortality in EP1+/+ 
mice.  A.  Survival of EP1+/+ and EP1-/- mice.  EP1+/+ mice experience a high 
mortality rate after implantation of the Ang II minipump (60 %, N=58) which is 
significantly reduced in EP1-/- mice (25 %, N=35). Kaplan Meier survival curves 
for each genotype are plotted, **P = 0.004.  B.  Survival of EP1+/+ modified 
protocol groups.  Survival curves were plotted indicating reduced mortality in all 
modified protocol groups.  Nphx/DOCA-NaCl/Ang II (data replotted from Figure 
1A) vs. Nphx/DOCA-NaCl, Nphx/Ang II or DOCA-NaCl/Ang II, P = 0.011, <0.005, 
or < 0.005.   
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the amount and organization of collagen surrounding the lesion was not 
significantly different in EP1+/+ and EP1-/- intact aneurysms (Figure 2.4, P = 
0.1925). 
 
Anasarca was observed in EP1+/+ mice 
A subset of EP1+/+ mice appeared to have substantial edema and displayed an 
increase in body weight, peaking approximately five days post-Ang II 
administration (Figure 2.5A).  Average body weight in EP1 +/+ cohort 
subsequently decreased due to mortality in the animals with the largest weight 
gain.  At baseline, EP1+/+ mice weighed more than EP1-/- mice though this 
difference was modest (EP1+/+ 26.6 ± 0.39 grams, EP1-/- 24.9 ± 0.68 grams, P 
= 0.024).  Body weight of EP1-/- mice was unchanged over the course of the 
study.  EP1+/+ mice had a significantly greater fraction water weight as 
compared to EP1-/- mice (Figure 2.5B, P = 0.0138), and aneurysm incidence 
was lower in mice which developed anasarca compared to mice without 
anasarca (33 % vs 76 %).  Anasarca is commonly a result of liver failure, 
nephrotic syndrome or heart failure (168,169).  Plasma alanine transaminase 
(ALT) activity was analyzed as a marker of liver function in Nphx/DOCA-
NaCl/Ang II treated EP1+/+ mice. ALT activity was not elevated above baseline 
values and no correlation with body weight was observed (Figure 2.6).  
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Figure 2.2.  Nphx/DOCA-NaCl/Ang II model induces aortic aneurysm formation.  
A.  Nphx/DOCA-NaCl/Ang II treatment resulted in formation of aneurysms and 
dissections in the thoracic and abdominal aorta.  Aortae were scored visually 
upon necropsy and representative images are shown.  B.  Post-mortem 
examination revealed 18 of 27 EP1+/+ mice and 6 of 15 EP1-/- mice developed 
aneurysms as a result of the Nphx/DOCA-NaCl/Ang II model.  Aneurysm severity 
was significantly reduced in EP1-/- mice compared to EP1+/+ mice. Fisher’s 
exact test, Severity < 3 vs. ≥ 3, P = 0.0344. 
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Figure 2.3.  Aortic inflammation is observed in EP1+/+ and EP1-/- mice.  A-D.  
Hematoxylin and eosin stained aortae (40X and 400X magnification).  A ruptured 
aneurysm in an EP1+/+ mouse (A, C) and a large aneurysm without rupture in an 
EP1-/- mouse (B, D). Vessel necrosis and perivascular inflammatory infiltration of 
macrophages and neutrophils are observed under high magnification (arrows, C 
and D).  L = vessel lumen, * = aneurysm.  E. Overall inflammation was scored 
based on H/E stained aortic sections.  No differences in inflammation were 
observed between EP1+/+ and EP1-/- aortas (P = 0.3975).  F.  
Immunohistochemistry for detection of macrophage, B cells, T cells and 
neutrophils in aortae was performed and scored in a blinded fashion by a 
comparative veterinary pathologist.   No differences in infiltrate were observed (P  
> 0.05).  G.  COX-2 mRNA in the thoracic and abdominal aortae 2-5 days post 
Ang II administration revealed a trend in increased COX-2 expression in the 
abdominal aorta of both EP1+/+ and EP1-/- mice post treatment.  No significant 
differences were observed by treatment or between genotypes (P > 0.05). 
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Figure 2.4.  Aortic fibrosis is observed in EP1+/+ and EP1-/- mice.  A.  
Extracellular matrix deposition was determined using Masson’s Trichrome stain 
(P = 0.1925).  B-E.  Masson’s trichrome stained aortae.  EP1+/+ aorta (B, D) with 
rupture displays less collagen organization.  EP1-/- aorta (C, E) with an intact 
aneurysm shows well developed and organized collagen (arrows) surrounding 
the aneurysm.  L = vessel lumen, * = aneurysm. 
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Figure 2.5. Body weight increases during Nphx/DOCA-NaCl/Ang II treatment in 
EP1+/+ mice.  A. Average body weight of EP1+/+ (N=50) and EP1-/- mice 
(N=22) throughout the duration of the experiment.  Body weight increased in 
EP1+/+ mice, but not EP1-/- mice, following Ang II administration.  Average body 
weight declined at approximately five days post-Ang II due to mortality in the 
subset of mice which gained the most weight (open symbols, EP1-/-; closed 
symbols, EP1+/+).  B.  Fraction water weight 5 days post-angiotensin II 
administration.  The fraction water weight was significantly greater in EP1+/+ 
mice, as compared to EP1-/- mice, P = 0.0138.  
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Figure 2.6.  Plasma alanine transaminase activity and body weight showed no 
correlation in EP1+/+ mice.  ALT activity was not elevated above expected 
baseline values (< 100 mU per mL) and no correlation with body weight was 
observed (R2 = 0.1368). 
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Modest renal injury was induced in EP1+/+ and EP1-/- mice 
The Nphx/DOCA-NaCl/Ang II model was initially developed to induce 
hypertensive renal damage on the C57BL/6 background (163).  To quantify renal 
damage in the EP1+/+ and EP1-/- mice, we monitored urinary albumin excretion, 
blood urea nitrogen, renal histopathology, and biomarkers of acute kidney injury, 
neutrophil gelatinase-associated lipocalin (Ngal) and kidney injury molecule-1 
(Kim-1) mRNA expression (Figure 2.7).  ACR and BUN were elevated but no 
significant differences were observed between genotypes (Figure 2.7A, B). Renal 
histopathology showed modest hypertensive renal damage compared to the 
contralateral kidney removed at time of uninephrectomy (Figure 2.7C).  Dilated 
tubules with moderate glomerulosclerosis and tubulointerstitial fibrosis were 
observed.  Significant increases in Ngal and Kim-1 mRNA expression in the 
kidney of EP1+/+ and EP1-/- mice were observed, though no differences were 
detected between genotypes (Figure 2.7D-E). 
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Figure 2.7.  Modest renal damage is observed in EP1+/+ and EP1-/- mice.  A.  
Urinary albumin excretion.  ACR was determined on spot urine collected 
throughout the duration of the experiment.  High albumin levels were detected in 
the urine after the addition of Ang II and no significant differences were observed 
in ACR between the genotypes.  Fisher’s Exact test, P = 0.4559.  B.  Blood urea 
nitrogen levels were modestly increased by the end of the full model as 
compared to baseline in both genotypes (EP1+/+ P = 0.0382, EP1-/- P = 0.0132), 
though no differences were observed in the degree of BUN levels between the 
genotypes (P = 0.5867).  C. Renal histopathology.  Masson’s trichrome stain 
revealed modest hypertensive renal damage observed in both genotypes 
following full model treatment (right panels) and compared to normal kidneys 
removed at time of uninephrectomy (left panels).  Specifically, dilated tubules 
with moderate glomerular sclerosis and tubulointerstitial fibrosis were observed.  
D and E.  Quantification of Ngal and Kim-1 mRNA expression in whole kidneys.  
Expression of clinically used renal injury biomarkers, Ngal and Kim-1, revealed 
significant increases in both genotypes treated with the full model (Ngal: EP1+/+ 
P = 0.0029, EP1-/- P = 0.0008; Kim-1:  EP1+/+ P = 0.007, EP1-/- P = 0.0002), 
though no significant differences between EP1+/+ and EP1-/- mRNA levels were 
observed (Ngal P = 0.8609, Kim-1 P = 0.4931). 
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Cardiac function is reduced in EP1+/+ and EP1-/- mice  
No structural differences in the heart were observed by echocardiography 
between EP1+/+ and EP1-/- mice at baseline.   A modest increase in ejection 
fraction and fractional shortening was observed in EP1-/- mice at baseline.  At 
five days post-Ang II administration, EP1+/+ had increased left ventricular 
posterior wall (LVPWd) and interventricular septum diastolic diameters (IVSd).  
EP1-/- mice had increased IVSd, though no significant change in LVPWd was 
observed.  EP1+/+ and EP1-/- mice displayed increased left ventricular interior 
diameter, though no differences were observed between genotypes.  Cardiac 
function was significantly reduced in both genotypes upon treatment with 
Nphx/DOCA-NaCl/Ang II, as demonstrated by decreased fractional shortening 
and ejection fraction (Table 2.1).  Additionally, heart weights of EP1+/+ and EP1-
/- mice after treatment with Nphx/DOCA-NaCl/Ang II showed no significant 
difference between the genotypes (EP1+/+: 198.9 ± 9.6 grams N = 21, EP1-/-: 
190.0 ± 4.3 grams N = 17, P = 0.461). 
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Hypertension was less severe in EP1-/- mice than EP1+/+ mice 
To determine the effect of disruption of the EP1 receptor on blood pressure in 
Nphx/DOCA-NaCl/Ang II treated animals, intracarotid blood pressure was 
determined in EP1+/+ and EP1-/- mice two days post-Ang II administration 
(Figure 2.8).  MAP was significantly increased compared to untreated animals in 
both EP1+/+ (76.79 +/- 5.33 mm Hg baseline vs. 128.8 +/- 5.08 mm Hg, P = 
0.0004) and EP1-/- mice (74.36 +/- 5.61 mm Hg baseline vs. 102.4 +/- 7.77 mm 
Hg, P = 0.0423).  However, the rise in MAP was significantly lower in EP1-/- 
compared to EP1+/+ mice (P = 0.0295).   
 
Reduction of blood pressure protected against mortality 
Fifteen EP1+/+ and EP1-/- mice treated with Nphx/DOCA-NaCl/Ang II were 
administered the antihypertensive agent hydralazine. Hydralazine treatment 
significantly reduced MAP in EP1+/+ mice (106.1 +/- 5.76 mm Hg vs. 128.8 +/- 
5.08 mm Hg, P = 0.024), and but had no significant effect on EP1-/- mice (Figure 
2.9A, 99.47 +/- 4.82 mm Hg vs. 102.4 +/- 7.77 mm Hg, P = 0.762).  A significant 
decrease in the incidence of mortality was observed in EP1+/+ but not EP1-/- 
mice (Figure 2.9B, P = 0.007 and P = 0.642 respectively).  Hydralazine treatment 
reduced aneurysm incidence and severity in EP1+/+ though this did not achieve 
statistical significance (Figure 2.9C, P > 0.05).  Anasarca was not observed in 
hydralazine treated EP1+/+ (Body weight 5 days post-Ang II: 21.40 +/- 0.65 
grams) as compared to untreated EP1+/+ mice (Body weight 5 days post-Ang II: 
32.28 +/- 1.59 grams, P < 0.0001). 
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Figure 2.8.  Mean Arterial Pressure is increased in EP1+/+, and blunted in 
EP1-/-, mice.  Intracarotid blood pressure was measured in EP1+/+ and EP1-/- 
mice two days post-Ang II administration under ketamine and inactin anesthesia.  
MAP was elevated in both groups compared to baseline (EP1+/+ ##P = 0.0004, 
EP1-/- #P = 0.0423) but was significantly lower in EP1-/- compared to EP1+/+ two 
days post-Ang II (*P = 0.0295). 
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Figure 2.9.  Hydralazine treatment reduced mortality in EP1+/+ but not EP1-/- 
mice. A.  Mean arterial pressure was measured in EP1+/+ and EP1-/- mice 
treated with hydralazine at 2 days after Ang II administration and compared to 
existing data shown in figure 2.7.  EP1+/+ with and without hydralazine, P = 
0.024. EP1-/- with and without hydralazine, P = 0.762.  B.  Mortality observed in 
EP1+/+ mice was significantly reduced by treatment with hydralazine, ***P = 
0.007. No change was observed in EP1-/- mice, P = 0.642.  C.  Aortic aneurysm 
severity.  Aneurysm severity was decreased in EP1+/+ mice treated with 
hydralazine (P > 0.05). 
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Discussion 
 
Disruption of the EP1 receptor affords substantial protection in the 
Nphx/DOCA-NaCl/Ang II evoked hypertension.  The incidence of mortality was 
significantly decreased and appeared to result from reduction in MAP.  Mortality 
was a result of ruptured aortic aneurysm or occurred after developing anasarca.  
The results presented here are consistent with previous studies demonstrating 
the role of EP1 in modulating the rise in MAP in response to Ang II (85), and 
further reveal the protective effect disruption of the EP1 receptor has on end-
organ damage. 
There are several limitations to these studies which deserve mention.  
First, high mortality observed in EP1+/+ mice confounds the analysis of 
measurements taken after implantation of Ang II, such as cardiac and renal 
function, since the analyses are only performed on surviving mice.  Second, 
there was a modest (<10 %), though statistically significant difference in body 
weight observed between EP1+/+ and EP1-/- mice.  Although the dosage of Ang 
II was adjusted by weight, the dosage of the DOCA pellet was not.  However, 
one would predict the genotype receiving the greater dose/weight (EP1-/-) would 
have the worse phenotype, and this is opposite what we observed.  Lastly, 
EP1-/- mice were observed to have lower blood pressure than EP1+/+ mice 
following treatment with the Nphx/DOCA-NaCl/ Ang II model.  This is consistent 
with our previously published data (170) suggesting EP1 mediates part of Ang II-
induced hypertension.  In this model we measured MAP at baseline or after 
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treatment with all three model components; it is possible that EP1 also 
contributes to hypertension induced by Nphx or DOCA-NaCl as well. 
 Current models of aortic aneurysm include a combination of 
hyperlipidemic mice or high fat diet with modulation of the renin-angiotensin-
aldosterone axis, or aberrant production of extracellular matrix components 
(171).  Ang II-induced aortic aneurysms are characterized by accumulation of 
macrophages in the adventia and media, disruption of elastin fibers, expansion of 
the lumen, thrombus formation and disordered extracellular matrix deposition 
(172).  These characteristics were also observed in the Nphx/DOCA-NaCl/Ang II 
model, although no significant differences in macrophage accumulation, matrix 
deposition, or COX-2 mRNA expression were detected between the two 
genotypes.  It should be noted that the aneurysms and dissections observed in 
this model occur after acute severe hypertension and although the pathology 
appears similar to that observed in human disease, the disease genesis may not 
be.  In humans, development of a true aneurysm is a slowly progressing disease 
initiating with local inflammation, disruption of the connective tissue matrix, and is 
often associated with atherosclerosis.  In contrast, development of false 
aneurysm, or dissection as a result of a tear in the intima, can occur more acutely 
by a sudden large rise in blood pressure or direct injury and may be more 
representative of the damage induced by the Nphx/DOCA-NaCl/Ang II model.  
Our data demonstrate that protection observed when EP1 is disrupted is likely 
due to the prevention of a large rise in blood pressure, since treatment with 
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hydralazine phenocopied EP1-/- mice.  This does not eliminate the possibility that 
EP1 receptors might also provide protection directly at the target tissue.   
Data exist suggesting a role for prostaglandins, in particular PGE2, in 
aortic aneurysm formation.  COX-2 initiates the production of prostaglandins, and 
its expression is induced by infusion of angiotensin II in the smooth muscle of the 
aorta surrounding aneurysms (166).  Furthermore, either selective inhibition of 
COX-2 or genetic deletion of COX-2 significantly reduced aortic aneurysm 
formation and macrophage infiltration (166,167).  Deletion of microsomal PGE 
synthase-1, which transforms the product of COX-2 metabolism into PGE2, has 
also been demonstrated to reduce aortic aneurysm formation and oxidative 
stress in LDLR-/- mice with an angiotensin II infusion (160), suggesting PGE2 
plays an important role in development of aneurysms and the EP receptors may 
be viable targets for treatment of aneurysm progression. 
Previous reports of the role of EP1 in renal injury are contradictory.  In 
spontaneously hypertensive rats, treatment with an EP1 antagonist reduced 
proteinuria and tubulointerstitial damage (87), while in anti-GBM nephrotoxic 
serum nephritis genetic deletion of EP1-/- in mice resulted in enhanced 
mesangial expansion and tubular dilation and increased blood urea nitrogen and 
serum creatinine (173).  In our studies, modest hypertensive renal damage was 
observed, although no significant differences in renal function were detected 
between genotypes.  However, our interpretation was confounded by the 
differential mortalities in EP1+/+ and EP1-/- mice, potentially biasing our results.  
Examination of renal histopathology at time points prior to significant mortality 
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failed to detect any severe renal damage or differences between the genotypes.  
This suggests the role of EP1 in renal damage is highly context dependent. 
Anasarca, or extreme generalized edema, can occur in many disease 
settings.  It is commonly a result of liver failure, nephrotic syndrome or heart 
failure (168,169).  In our Nphx/DOCA-NaCl/Ang II model, a subset of EP1+/+ 
mice developed severe anasarca prior to mortality, while EP1-/- mice were 
protected.  The EP1 receptor has previously been shown to be natriuretic (85).  
With this paradigm, one might predict EP1-/- mice would retain more salt and 
water; however in our results we demonstrate that EP1+/+ mice gain excessive 
fluid volume that is not observed in EP1-/- mice.  This contradiction leads us to 
conclude that alterations in kidney function by disruption of EP1 do not play a 
dominant role in development of the observed edema.  Additionally, cardiac 
function was reduced to similar degrees in EP1+/+ and EP1-/- mice.  Edema was 
prevented by treatment with hydralazine, suggesting elevation in blood pressure 
was responsible for development of edema.  We hypothesize that hypertension 
induced by DOCA-NaCl and Ang II results in volume loading and enhanced 
vasoconstriction, which places excessive stress on the vascular wall leading to 
enhanced permeability, resulting in edema and susceptibility to dissections and 
rupture.  Future experiments will be required to identify whether vascular 
permeability differences are observed between EP1+/+ and EP1-/-mice. 
The EP1 receptor plays an important role in the development of 
hypertensive damage.  In the Nphx/DOCA-NaCl/Ang II model, disruption of EP1 
results in increased incidence of survival, lessened aneurysm severity and the 
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absence of anasarca.  This effect is a result of a reduced rise in blood pressure 
observed in EP1-/- mice, and suggests the EP1 receptor may be a viable 
pharmaceutical target for the treatment of hypertension and subsequent organ 
damage.  Furthermore the Nphx/DOCA-NaCl/Ang II model may prove to be a 
useful tool for studying the pathology of aortic aneurysm and dissection formation 
in a setting of acute severe hypertension. 
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CHAPTER III 
 
DISRUPTION OF EP3 IS PROTECTIVE AGAINST MORTALITY IN A MOUSE 
MODEL OF HYPERTENSION 
 
Introduction 
 
There is a strong association between hypertension and progressive renal 
failure, and mitigation of hypertension is a major therapeutic goal for the 
prevention of end-stage renal disease.  A number of pharmacologic agents are 
available for the treatment of hypertension including those that affect the renin-
angiotensin aldosterone system such as angiotensin converting enzyme 
inhibitors, angiotensin receptor blockers and more recently, the introduction of 
renin inhibitors (11,174-178).  Angiotensin II mediates its effects via two GPCRs, 
designated AT1 and AT2, which are distinguished by their pharmacology and the 
signal transduction pathways that they activate (175,176,179). The AT1 receptor 
is the target for the anti-hypertensive receptor antagonist ARBs (180).  AT1 
receptor activation leads to a number of signal transduction pathways including 
increases in intracellular Ca++ and activation of cPLA2 (180-188), a critical 
regulatory step in the formation of PGs.  PGs, which are oxygenated metabolites 
of the essential fatty acid arachidonic acid, are themselves modulators of blood 
pressure and evidence suggests that blockade of one or more prostaglandin 
receptors may be useful for the treatment of hypertension. Recent evidence 
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suggests that at least one PGE2 receptor may play a role in the actions of the 
RAAS on blood pressure (85). 
PGs are potent mediators of a wide range of physiological actions 
including inflammation, modulation of smooth muscle tone and water and ion 
transport in the kidney (98,189). The five primary bio-active prostanoids PGE2, 
PGF2α, PGD2, PGI2, and TXA2, activate a family of specific GPCRs, EP for E-
prostanoid receptors, FP, DP, IP and TP receptors respectively (98).  The EP 
receptors are unique among the PG receptors, in that four receptors, designated 
EP1 through EP4, have been described for PGE2 each encoded by a distinct 
gene. PGE2 has been demonstrated to act as either a pressor or depressor 
depending upon the EP receptor activated (17,19,79,99,157,190-193). Upon 
acute infusion, PGE2 is a vasodepressor in both humans and mice (17,138,150). 
Previous studies with knockout mice have shown that this depressor effect is 
primarily due to the activation of the EP2 receptor (139). When the EP2 receptor 
is deleted, the loss of the depressor response unmasks a PGE2 pressor 
response, suggesting a balance of pressor and depressor receptors activated by 
PGE2. The pressor response is mediated by the EP3 and EP1 receptors 
(85,139). 
Development of models for the study of hypertension and renal damage 
that recapitulate human disease have been challenging, particularly on the 
C57BL/6 background (194,195).  A model of hypertension that causes renal 
damage on the C57BL/6 background has been recently reported (163). This 
model which employs a combination of uninephrectomy, deoxycorticosterone 
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acetate (DOCA), high sodium intake and Ang II, was reported to initiate renal 
damage over a relatively short time course of five weeks.  Using this model, the 
effects of the EP3 receptor on hypertension and renal damage were evaluated.   
 
Experimental Procedures 
 
Materials 
Angiotensin II was purchased from EMD Gibbstown, NJ, and DOCA was 
purchased from Innovative Research of America, Sarasota, FL, USA. Osmotic 
minipumps were purchased from DURECT Corporation, USA. 
 
Induction of Hypertension 
EP3-/- or EP3+/+ mice were uninephrectomized under ketamine/xylazine 
anesthesia two weeks before the start of the study.  At day 0, mice received 
subcutaneous implantation of a 50 mg DOCA pellet and were given ad libitum 
access drinking water containing 1 % NaCl. At day 7, an osmotic mini-pump 
(Alzet model 1002) delivering 1.5 ng/min/gram body weight angiotensin II was 
implanted subcutaneously.  At day 19 or 21, the animals were euthanized. 
Tissues were removed for examination by histological study or snap frozen for 
RNA and protein analysis. Four separate studies were performed with six to eight 
EP3-/- animals in each study and seven or eight EP3+/+ littermates or 
commercially obtained C57BL/6J mice (The Jackson Laboratory, Bar Harbor, 
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ME).  A total of 34 EP3+/+ mice and 27 EP3-/- mice were used.  All experimental 
studies were approved by the IACUC of Vanderbilt University Medical Center. 
 
Measurement of Systolic Blood Pressure 
Systolic BP was determined in conscious mice using a computerized tail-cuff 
system (Visitech systems BP-2000 Blood Pressure Analysis System, Apex NC, 
USA) in the Mouse Metabolic Phenotyping Core at Vanderbilt University Medical 
Center. Mice were trained for four days minimizing physiologically apparent 
stress. Each measurement is the average of at least 10 consecutive readings 
after stabilization of blood pressure. 
 
Intracarotid blood pressure measurement 
Intracarotid blood pressure was measured under ketamine (25 mg/kg) and 
inactin (100 mg/kg) anesthesia delivered intraperitoneally.  Mice were placed on 
a thermal pad and a PE-10 catheter was inserted into the left carotid artery.  The 
catheter was connected to a TXD-310 transducer and blood pressure was 
measured using a Digi-Med BPA 400 (Micromed).  Mice were equilibrated 30-60 
minutes until stable values were attained.  Ten minute blood pressure 
measurements were collected and average mean arterial pressure (MAP) is 
plotted. 
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Determination of Blood Urea Nitrogen levels 
To assess renal function, BUN levels were determined using Infinity Urea liquid 
stable reagent (Thermo scientific, USA). Heparinized blood was obtained from 
saphenous vein and plasma was stored at -80 °C until assayed. 
 
Assessment of Renal Histopathology 
Mice were humanely euthanized and tissues fixed overnight in 10 % neutral 
buffered formalin.  Tissues were then processed routinely, embedded in paraffin, 
sectioned at 5 microns, stained with hematoxylin and eosin and evaluated by 
light microscopy. Kidney injury was scored by a renal pathologist who calculated 
the percent of tubules with cell necrosis, loss of brush border, cast formation, and 
tubular dilation as follows: 0, none; 1, <10 %; 2, 11-25 %; 3, 26-45 %; 4, 46-75 %; 5, 
>76 %.  At least 10 fields (x200) were reviewed for each slide in a blinded fashion. 
 
Statistical Analysis 
Data were analyses using ANOVA or Student’s t test were performed with 
GraphPad Prism software (GraphPad Software Inc., CA, USA) and are shown as 
means ± SEM. Survival curves were evaluated by the Kaplan-Meier method. P < 
0.05 was considered statistically significant for all studies. 
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Results 
 
Uninephrectomy/DOCA-NaCl/Ang II model of Hypertension caused 
significant mortality. 
 
C57BL/6 animals were treated using the recently reported 
uninephrectomy/DOCA-NaCl/Ang II model of hypertension (163).  In contrast to 
the published report, this model resulted in significant mortality after implantation 
of the Ang II minipumps. Deletion of the EP3 receptor was protective; EP3+/+ 
mice having 36 % survival while EP3-/- mice had 53% survival (P =0.037; Fig. 
3.1). 
In the EP3+/+ group, mice displayed severe anasarca, while EP3-/- rarely 
developed anasarca even in the subset of mice that died. This is reflected in the 
change in body weight of mice from the initiation of the study to time of death, or 
the end of the study (Fig. 3.2A).  While EP3+/+ had a marked increase in body 
weight, the EP3-/- mice had no significant change in body weight.  This 
difference in body weight was transient over the course of the study (Fig 3.2B).  
The transient change in body weight observed in the EP3+/+ group was a result 
of higher mortality observed in mice with the greatest increase in body weight 
(Figs. 3.2).  
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Figure 3.1. The uninephrectomy/DOCA-NaCl/Ang II model resulted in significant 
mortality. Significant mortality was observed in both EP3+/+ (solid line), and 
EP3-/- genotypes (broken line). The survival curves of two groups were 
compared using Kaplan-Meier analysis.  Initial EP3+/+, N = 34, EP3-/-, N = 27, P 
= 0.037. 
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Blood pressure was elevated in both genotypes, but less in EP3-/- mice 
The EP3 receptor has vasopressor action, and therefore we hypothesized that 
significant changes in blood pressure between the two groups might underlie the 
decreased mortality in the EP3-/- mice.  Baseline blood pressure was not 
significantly different between genotypes in untreated animals (EP3+/+ 108.8 ± 
1.7 mm Hg, EP3-/- 107.1 ± 1.6 mm Hg P = 0.47, Figure 3.3A). Concurrent 
treatment with DOCA salt water and Ang II for two weeks resulted in elevated 
blood pressure as reported previously in this model.  Although there was a 
dramatic increase in systemic blood pressure over time in both experimental 
groups terminal SBP was not different between the two groups (EP3+/+ 182.6 ± 
5.0 mm Hg, EP3-/- 193.1 ± 4.5 mm Hg P = 0.131; Fig. 3.3B).  However, 
measurement of blood pressure by direct carotid catheterization under 
anesthesia at 2 or 14 days post Ang II revealed a significantly lower MAP in EP3-
/- mice as compared to EP3+/+ mice (EP3+/+ 129.7 ± 2.8 mm Hg, EP3-/-  116.6 
± 5.4 mm Hg, P = 0.0314, Figure 3.3C). 
 
EP3+/+ and EP3-/- mice have modest renal damage 
The uninephrectomy/DOCA-NaCl/Ang II model was developed to induce 
hypertensive renal damage on the C57BL/6 background. Histologic analyses 
indicated similar degrees of renal injury in the EP3+/+ and the EP3-/- mice. The 
kidneys were characterized by multifocal, segmental to global glomerular 
microangiopathy and acute renal tubular necrosis with protein casts.  Distinction 
between the EP3+/+ and EP3-/- renal damage was limited to the renal tubules,  
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Figure 3.2.  Body weight increased in EP3+/+ mice but not EP3-/- mice. A. The 
difference in terminal body weight and initial body weight was determined. 
EP3+/+ gained significantly more weight than EP3-/- mice. EP3 +/+, n = 34, 
EP3-/- n= 27 ** P = 0.0032. B. After implantation of the Ang II pump EP3+/+ mice 
increased body weight. Initial EP3+/+, n = 34, EP3-/-, N = 27. 
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Figure 3.3. Both EP3+/+ and EP3-/- animals had significant increases in systolic 
blood pressure (SBP). A. Baseline SBP was measured in untreated EP3+/+ or 
EP3-/- mice by the tail cuff method (EP3+/+, n = 37, EP3-/-, n= 28, P = 0.47). B. 
SBP for the two groups over the course of the hypertension study are shown. 
Data were analyzed by two-way ANOVA (genotype and time). Initial EP3+/+, n = 
34, EP3-/-, n= 27, all surviving mice were analyzed at each time point.  There 
was a statistically significant change in blood pressure over baseline with time in 
each genotype (P < 0.0001). There was no effect of the genotype on SBP over 
time (P = 0.29).  C.  Intracarotid blood pressure was measured at 2 and 14 days 
post Ang II.  MAP was significantly lower in EP3-/- mice as compared to EP3+/+ 
mice (P = 0.0314).  Wildtype data from figure 2.7 are replotted as EP3+/+ MAP. 
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Figure 3.4.  Modest end organ renal damage is observed in EP1+/+ and EP1-/- 
mice. A. H/E staining reveals glomerular microangiopathy and proteinaceous 
casts in the EP3+/+ and B. EP3-/- renal cortex (200x).   Asterisks indicate 
glomeruli with segmental microangiopathies.  Arrows indicate proteinaceous 
tubular casts.  There is a mild decrease in tubular disease in the EP3-/- as 
compared to EP3+/+ kidneys.  C. H/E staining of the corticomedullary junction in 
the EP3+/+ mouse kidney shows acute tubular necrosis and proteinaceous cast 
formation.  In the more severely affected areas, tubular epithelial cells are 
swollen and vacuolated and lose intercellular and basement membrane 
attachments (Arrows).  D. There is a modest decrease in damage seen in the 
EP3-/- mice (200x). Kidney tissue from eight EP3+/+ and ten EP3-/- mice were 
examined. 
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Figure 3.5. Quantitation of renal damage. A. Kidney injury was scored by 
pathologist Kelli Boyd, DVM as described in the Methods section.  At least 10 fields 
(x200) were reviewed for each slide in a blinded fashion.  No difference was seen 
between EP3+/+ and EP3-/-. B. Blood Urea Nitrogen (BUN) was determined as 
described in the Methods section. A significant increase in BUN was observed for 
both genotypes, comparing terminal BUN (n = 11 or 12 in each group) to 
baseline BUN values (n = 6 or 7 in each group, 2 way ANOVA P < 0.0001).  The 
contribution of genotype to the BUN value was not significant.   
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where the tubular injury was slightly decreased in the EP3-/- mice as compared 
to EP3+/+ mice (Fig. 3.4).  Overall renal damage was quantitated as described in 
the methods section, and no significant differences were observed in renal 
histopathological score (Fig 3.5A). Similarly, although both EP3+/+ and EP3-/- 
genotypes exhibited elevated BUN levels when subjected to the Nphx/DOCA-
NaCl/AngII model (P < 0.0001) no statistically significant increase in terminal 
BUN of EP3+/+ as compared to EP3-/- animals was observed (baseline: EP3+/+ 
BUN 20.6 ± 3.8 mg/dL, EP3-/- 28.0 ± 3.5 mg/dL; terminal: EP3+/+ BUN = 53.7 ± 
6.0 mg/dL, EP3-/- 41.8 ± 3.4 mg/dL 2 way ANOVA P > 0.05; Fig. 3.5B). 
 
Discussion 
 
These studies demonstrated that deletion of the EP3 receptor resulted in 
decreased mortality and modestly reduced hypertension in a mouse model of 
severe hypertension.  Although both EP3+/+ and EP3-/- animals displayed 
increased BUN and pathological changes in the kidney, these changes were not 
significantly different between the genotypes. These studies were carried out on 
the C57BL/6 background, which is normally resistant to renal damage. A recent 
report described this model to induce hypertensive end organ damage on the 
C57BL/6 background strain (163).  We were able to induce renal damage in the 
present studies, although we observed substantial differences compared to the 
reported findings.  Most strikingly the EP3+/+ mice developed severe edema and 
mice in both groups experienced significant mortality.  This was surprising as no 
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mortality was reported in the original description of the model, nor was a gain in 
weight reported.  The EP3 receptor opposes the diuretic action of vasopressin in 
the renal cortical collecting duct (196,197).  Loss of EP3 receptor might be 
expected to affect water balance, but in this case it should increase water 
retention in the EP3-/- animals, the opposite of the observed effect of anasarca in 
the EP3+/+ mice.  Previous studies have shown that mice with a disruption of the 
EP3 receptor concentrated urine normally in response to a range of physiologic 
stimuli, again suggesting that renal effects of the loss of the EP3 receptor are not 
playing a critical role in the phenotypic differences observed here (117). 
Using tail cuff measurements, we observed SBP of near 200 mm Hg, 
almost 60 mm Hg higher than observed in the previous report.  No deaths were 
observed in our study until after implantation of the Ang II pump, suggesting that 
the presence of exogenous Ang II is critical to the cause of death.  Deletion of the 
EP3 receptor was associated with increased survival from 36 % in the EP3+/+ 
group to 53 % in the EP3-/- group.  The EP3 receptor has been implicated in the 
pressor effect of PGE2 (139).  It might be anticipated that deletion of this receptor 
would lead to lower blood pressure, and this would underlie its protective effect.  
In the present studies we noted that the EP3-/- mice had modestly reduced 
hypertension compared to EP3+/+ mice.  This suggests the protective effect of 
EP3 may be due to changes in blood pressure.  These results are consistent with 
studies presented in Chapter II.  Futhermore, the degree of hypertension 
correlates with protection against mortality.  Given these results, these studies 
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that blockade of the EP3 and/or EP1 receptor would be protective from 
hypertension and its downstream consequences. 
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CHAPTER IV 
 
CONTRIBUTION OF THE EP1 RECEPTOR IN HYPERTENSIVE RENAL 
DAMAGE 
 
Introduction 
 
Chronic kidney disease (CKD) is a major public health concern.  The 2010 
annual report from the United States Renal Data Systems estimated 
approximately 600,000 patients had end-stage renal disease (ESRD) in 2008, 
which cost the US $39.5 billion/year.    Additionally, the incidence and prevalence 
of CKD continues to rise in the United States creating a need for novel 
therapeutic agents (198). 
Development of new onset kidney disease is strongly associated with 
hypertension, diabetes, smoking and low HDL cholesterol (199).  In men, 
baseline blood pressure ≥ 120/80 mm Hg strongly increased the development of 
ESRD as demonstrated by the Multiple Risk Factor Intervention Trial (200).  
Several other randomized clinical trials have also demonstrated correlations 
between hypertension and CKD (201-208), including the RENAAL (Reduction of 
Endpoints in NIDDM with Angiotension II Antagonist Losartan) trial which showed 
that each 10 mm Hg rise in systolic blood pressure resulted in an increased risk 
of ESRD or death of 11 % (209).  Therefore, the treatment of renal disease is 
very closely tied to the treatment of hypertension.   
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Kidney disease is characterized by changes that involve renal 
inflammation followed by interstitial fibrosis, atrophy of the renal tubules, and 
glomerulosclerosis (210).  Agents that block the renin-angiotensin-aldosterone 
system, such as ARBs, ACEi, and renin inhibitors, are among the most 
commonly used therapeutics for treatment of hypertension and renal damage.  
AT1 receptors mediate the majority of Ang II induced effects.  AT1 is a G protein 
coupled receptor, which canonically couples to Gq G-proteins, but is also known 
to activate multiple second messenger signal transduction pathways including 
extracellular signal-regulated kinases 1 and 2, activation of phospholipases, 
inhibition of adenylate cyclase, and stimulation of tyrosine phosphorylation and 
Akt (211).  Although classically Ang II has been thought to primarly modulate 
blood pressure and renal damage through vasoconstriction and aldosterone-
induced sodium retention, it is now appreciated to also have affects on 
proteinuria, inflammation, proliferation, apoptosis, and fibrosis (212,213), thus the 
benefits of blockade of RAAS often extend beyond that of just blood pressure 
control (178,214-222).  In these studies, the ARBs and ACEi had effects that 
occur in the absence of a blood pressure change or had a greater change than 
observed with a drug which reduced blood pressure comparably.  One such 
example utilized a 5/6th nephrectomy model on male Munich-Wistar rats.  Rats 
were treated with either an ACEi, enalapril, or a triple therapy of reserpine, 
hydralazine and hydrochlorothiazide (RAAS independent).  Both treatments 
normalized blood pressure, although only enalapril was able to reduce the 
development of proteinuria and glomerulosclerosis, suggesting the 
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renoprotective effects of enalapril are independent of blood pressure reduction 
(216). 
As mentioned previously, agonism of AT1 receptors can activate 
phospholipases, which yields products such as prostaglandins.  PGE2 is a known 
modulator of blood pressure and renal disease.  PGE2 can act as either a 
vasopressor or a vasodepressor (17-19,138).  This antagonistic property of PGE2 
can be explained by the existence of four PGE2 receptors, designated EP1 
through EP4, each with distinct tissue localization and characteristic signal 
transduction pathways.  Using pharmacologic agents and genetics, it has been 
demonstrated that the EP1 and EP3 receptors primarily mediate the pressor 
response of PGE2, while the EP2 and EP4 receptors mediate the depressor 
response (17,79,85,99,134,138-140).  Of most interest, the EP1 receptor has 
been shown to mediate Ang II-induced hypertension (85).  EP1-/- mice have 
blunted pressor responses to both acute and chronic Ang II administration (85).  
Furthermore, in isolated vessel preparations pre-treatment with the EP1 selective 
antagonist SC51322 reduced Ang II mediated vasoconstriction (85).   Given that 
EP1 mediates some of the blood pressure and vasoconstrictor effects of Ang II 
and RAAS, it is of great interest whether EP1 contributes to renal fibrosis and 
CKD, possibly in a blood pressure independent manner similar to that of AT1. 
EP1 blockade has been shown to positively affect renal function in a 
rodent model of human malignant hypertension (87).  Stroke-prone 
spontaneously hypertensive rats were treated with vehicle or a selective EP1 
antagonist.  Although no differences were observed in blood pressure, treatment 
84 
 
with the EP1 antagonist reduced tubulointerstitial fibrosis, lessened urinary 
protein excretion, and blunted the drop in plasma creatinine levels.  This 
suggests blockade of the EP1 receptor has a positive effect on renal function and 
may be a therapeutically relevant target (87).  Nonetheless, it is imperative to 
continue investigating the contribution of EP1 to renal damage in order to 
demonstrate whether this is model specific and can be observed with both 
pharmacologic as well as genetic manipulation.  Therefore, EP1+/+ and EP1-/- 
mice were studied in a model hypertensive renal damage. 
 
Experimental Procedures 
 
Animal procedures 
Hypertension-induced renal damage was obtained utilizing a previously 
published model involving uninephrectomy and Ang II administration (214), with 
the exception of using the 129S6 background instead of FVB/N.  Twelve week 
old 129S6/SvEvTac (EP1+/+, Taconic, USA) and EP1-/- mice (85) underwent 
unilateral nephrectomy and implantation of a subcutaneous osmotic minipump 
delivering Ang II (1.4 mg/kg/day) for 6 weeks as illustrated in Figure 4.1.  In some 
cases, uninephrectomy was performed in the absence of Ang II administration.   
Blood was collected at baseline and 6 weeks post-treatment for measurement of 
BUN and GFR.  Every two weeks, systolic blood pressure was measured and 
urine collected.  Animals were maintained in an AAALAC accredited rodent 
facility in individually ventilated microisolator cages on a 12:12 light dark cycle.  
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All procedures were done in accordance with the policies of the Institutional 
Animal Care and Use Committee at Vanderbilt University.  
 
  
 
 
 
 
  
 
 
Figure 4.1 Experimental Design of Nphx + Ang II induced renal damage.  EP1+/+ 
and EP1-/- mice underwent uninephrectomy + implantation of an Ang II osmotic 
minipump delivering 1.4 mg/kg/day, uninephrectomy only, or no treatment and 
followed for 6 weeks. 
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Measurement of Systolic Blood Pressure 
Systolic BP was determined in conscious mice using a computerized tail-cuff 
system (Visitech systems BP-2000 Blood Pressure Analysis System, Apex NC, 
USA) in the Mouse Metabolic Phenotyping Core at Vanderbilt University Medical 
Center. Mice were trained for four days minimizing physiologically apparent 
stress. Each measurement is the average of at least 10 consecutive readings 
after stabilization of blood pressure. 
 
Determination of Blood Urea Nitrogen levels 
To assess the renal function, blood urea nitrogen (BUN) was determined using 
an iSTAT-1 analyzer (Abbott Point of Care Inc., New Jersey, USA).   Whole 
blood was obtained from saphenous vein and immediately assayed utilizing 
Chem8+ cartridges. 
 
Determination of urinary albumin/creatinine ratios 
Albumin/Creatinine ratios (ACR; expressed as mg albumin/mg creatinine) were 
measured from 20-200 μL volumes of spot urine using Albuwell M ELISA kit, and 
urinary creatinine was measured using the Creatinine Companion (Exocell, 
Philadelphia, USA).   
 
Glomerular filtration rate determination 
GFR was determined based on plasma FITC–inulin clearance following a single 
bolus injection (223).   Briefly, dialyzed FITC-inulin solution was injected into tail 
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vein.  Approximately 20 uL of blood was collected via saphenous venesection at 
3, 7, 10, 15, 35, 55 and 75 minutes post injection for measurement of FITC 
concentration.  Plasma samples were buffered to pH 7.4 with 500 mM HEPES 
and fluorescence was determined using 485-nm excitation and read at 538-nm 
emission. Parameters were estimated by two-phase exponential decay nonlinear 
regression of plasma fluorescence data (GraphPad Prism). GFR was calculated 
using the equation GFR = I/(A/α + B/β). 
 
Statistical Analysis 
Data are presented as means ± SEM, using GraphPad Prism software 
(GraphPad Software Inc., USA). Analysis utilized Student’s t test and two-way 
ANOVA. P < 0.05 was considered statistically significant for all studies. 
 
Results 
 
Hypertension was induced by uninephrectomy and Ang II 
We employed a model of hypertension (214) to investigate the contribution of 
EP1 receptors to the pathogenesis of hypertension-induced renal damage.  At 
baseline, SBP in EP1-/- mice was comparable to that of EP1+/+ mice (EP1+/+: 
117.8 ± 2.485 mm Hg, EP1-/-: 114.3 ± 3.853 mm Hg, Figure 4.2A).  Following 
uninephrectomy and Ang II administration, SBP increased in both EP1+/+ and 
EP1-/- mice, though no differences were detected between the two genotypes at 
any time point (Figure 4.2B). 
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Figure 4.2 Hypertension was induced by Nphx + Ang II administration.  A.  
Baseline systolic blood pressure was similar in EP1+/+ and EP1-/- mice (P = 
0.44, N = 17 or 20 mice).  B.  Treatment with the Nphx + Ang II model induced 
comparable hypertension in both EP1+/+ (solid symbols) and EP1-/- (open 
symbols) mice. (P < 0.0001 vs baseline).  No differences were detected between 
EP1+/+ and EP1-/- SBP.   
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Organ weight was increased in EP1+/+ and EP1-/- mice 
Heart and kidney weight were increased in both EP1+/+ and EP1-/- mice after 6 
weeks treatment with Nphx + Ang II.  Kidney weight was modestly increased by 
treatment with Nphx + Ang II in EP1+/+ and EP1-/- mice compared to baseline 
(Figure 4.3A).  Uninephrectomy alone decreased kidney weight in EP1+/+ mice, 
though no difference was observed in EP1-/- mice.  Heart weight was also 
significantly greater in Nphx + Ang II treated animals as compared to Nphx only, 
or untreated animals (Figure 4.3B).  No significant differences in heart weight 
were observed between EP1+/+ and EP1-/- mice, indicative of a similar degree 
of hypertension. 
 
Renal damage was induced by Nphx + Ang II treatment and reduced in  
EP1-/- mice 
 
Blood urea nitrogen was significantly elevated in EP1+/+ and EP1-/- mice with 
Nphx + Ang II (Figure 4.4A).  Interestingly, EP1-/- mice had modestly elevated 
BUN at baseline as compared to EP1+/+ mice.  Over the 6 week treatment 
period, EP1+/+ mice experienced a rise in BUN, even in the absence of Nphx or 
Ang II, while EP1-/- mouse BUN remained consistent unchanged.  The difference 
between genotypes at baseline complicates the interpretation of the data.  
Therefore, change in BUN was determined using paired data from mice treated 
with Nphx + Ang II.  Compared to baseline, six weeks post treatment EP1+/+ 
mice had a rise in BUN of 37 mg/dL, whereas EP1-/- mouse BUN rose only 17 
mg/dL (P = 0.007, Figure 4.4B).  Urinary ACR was measured every other week 
throughout the experiment, and revealed significantly lower urinary protein  
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Figure 4.3 Heart and kidney weight were increased in both EP1+/+ and EP1-/- 
mice after 6 weeks treatment with Nphx + Ang II.  A.  Kidney weight, expressed 
mg/gram body weight, was increased in EP1+/+ and EP1-/- mice compared to 
baseline by treatment with Nphx + Ang II (EP1+/+ P = 0.04, EP1-/- P = 0.001).  
Nphx alone decreased kidney weight in EP1+/+ mice (P = 0.005), though no 
difference was observed in EP1-/- mice.  B.  Heart weight, expressed mg/gram 
body weight, was significantly greater in Nphx + Ang II treated animals as 
compared to Nphx only, or untreated animals (P < 0.01 for both genotypes).  No 
significant differences were observed between EP1+/+ and EP1-/- mice (P > 
0.05).   
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Figure 4.4 BUN was increased by Nphx + Ang II treatment.  A.  Blood urea 
nitrogen was measured prior to start of the model or six weeks after treatment.  
At baseline EP1-/- mice had elevated BUN compared to EP1+/+ mice (*P < 
0.05).  Six weeks later, BUN was elevated over baseline in all treatment groups 
of EP1+/+, and Nphx + Ang II treated EP1-/- mice (## P < 0.004, #### P < 
0.0001).  B.  The change in BUN from baseline to six weeks treatment with Nphx 
+ Ang II revealed EP1-/- mice had an attenuated rise in BUN compared to 
EP1+/+ mice (**P = 0.007) 
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in EP1-/- mice compared to EP1+/+ mice (P < 0.0001, Figure 4.5A).  GFR was 
decreased in EP1+/+ and EP-/- mice treated with Nphx + Ang II, compared to 
untreated 18 week old mice, dropping 60 % in EP1+/+ mice and 40 % in EP1-/- 
mice (Figure 4.5B).  However, aging from 12 to 18 weeks of age resulted in a 
reduction in GFR in EP1-/- mice only. 
 
Discussion 
 
In the present study we examined whether genetic ablation of the EP1 
receptor affords renal protection in a model of hypertensive end-organ damage.  
The uninephrectomy and Ang II model resulted in functional renal damage 
including a rise in BUN, elevated ACR and reduced GFR, while genetic ablation 
of EP1 reduced the rise in BUN and decreased ACR.  These studies suggest the 
EP1 receptor plays an important role in hypertensive renal disease.   
Our results are consistent with Suganami et al., who showed that 
pharmacological blockade of EP1 reduced proteinuria and tubulointerstitial 
damage in stroke prone spontaneously hypertensive rats (87).  However, in anti-
GBM nephrotoxic serum nephritis, which occurs in the absence of elevated blood 
pressure, genetic deletion of EP1-/- in mice resulted in increased mesangial 
expansion, tubular dilation, BUN and serum creatinine (173).  Furthermore, no 
differences were observed in renal damage with genetic ablation of EP1 in the 
Nphx/DOCA-NaCl/Ang II model, although in this case only modest renal damage 
was induced and ablation of EP1 did substantially increase survival and protect 
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Figure 4.5 ACR and GFR following treatment with Nphx + Ang II.  A. Urinary ACR 
was measured every other week throughout the experiment, revealing 
significantly lower urinary protein in EP1-/- mice compared to EP1+/+ mice.  (2 
way ANOVA, ****P < 0.0001, N = 3-12 samples per point).  B.  GFR was 
decreased in EP1+/+ and EP-/- mice treated with Nphx + Ang II, compared to 
untreated 18 week old mice (EP1+/+ P =  0.001, EP1-/- P = 0.028).  Aging from 
12 to 18 weeks of age resulted in a reduction in GFR in EP1-/- mice only (#P = 
0.002). 
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against vascular defects (224).  This suggests the role of EP1 in renal damage is 
highly context dependent. 
Throughout these studies blood pressure was measured by tail cuff 
plethysmography.  Treatment with uninephrectomy and Ang II raised SBP as 
compared to uninephrectomy alone or no treatment.  However, EP1-/- mice had 
a similar degree of hypertension compared to EP1+/+ mice.  This is inconsistent 
with previous reports demonstrating that pharmacological blockade and genetic 
ablation of EP1 reduces blood pressure, modestly at baseline and exaggerated 
in a setting of hypertension, and administration of EP1 agonists results in an 
increase in blood pressure (79,85,224).  It is possible that blood pressure 
differences were not observed in our studies due to the lack of sensitivity of the 
tail cuff technique.  To address this, more accurate blood pressure 
measurements would need to be made utilizing a direct arterial catherization 
either anesthetized or by telemetry. 
 EP1-/- mice had a reduction in the rise in BUN from baseline vs 6 weeks 
post uninephrectomy and Ang II, as compared to EP1+/+ mice.  However, the 
raw values for BUN at 6 weeks post treatment failed to reach significance.  
Change in BUN reached significance because EP1-/- began the study with 
significantly higher BUN as compared to EP1+/+ mice.  Similarly GFR declined 
with age in untreated EP1-/- mice and not EP1+/+ mice although the sample size 
was small in this case.  This effect has not been observed previously, and it 
would be important to determine if this trend holds true in repeated experiments 
or is observed with prolonged treatment by pharmacological blockade in a 
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healthy animal.  This could indicate that treatment with EP1 antagonists would be 
better utilized for slowing the progression of renal damage and not advised for 
use in patients without renal damage. 
 In summary, genetic ablation of the PGE2 receptor EP1 affords protection 
against renal function decline as a result of hypertension.  This protection may be 
independent of blood pressure reduction.  These results suggest the EP1 
receptor may be a viable target for the treatment of renal damage. 
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CHAPTER V 
 
CONTRIBUTION OF THE EP1 RECEPTOR IN DIABETIC RENAL DAMAGE 
 
Introduction 
 
Diabetes is a disease characterized by high circulating blood glucose 
levels.  This can occur as a result of inadequate insulin production, the inability to 
properly respond to insulin, or both.  The prevalence of diabetes increases with 
age.  In 2010, approximately 11.3 % of adults over 20 years of age had diabetes, 
while 26.9 % of adults over 65 years of age were diabetic.  According to the 
CDC, in 2007 diabetes cost the US $174 billion, $116 billion of that composed of 
direct medical costs.  Diabetes is the leading cause of blindness, lower-limb 
amputation, and kidney failure, and also increases the risk of coronary heart 
disease, peripheral vascular disease and stroke (225). 
Diabetic nephropathy (DN) is a progressive disease which results in 
irreversible loss of kidney function.  The initial mechanism of damage occurs due 
to adaptive hyperfiltration which eventually leads to long term damage of the 
nephrons.  In type I diabetes, progression of DN begins within 5 years of onset of 
diabetes with glomerular hyperfiltration, which transitions into the presence of 
glomerular lesions without clinical disease or urinary albumin excretion (226-
228).  These lesions include thickening of the glomerular basement membrane 
and expansion of the mesangial cells.  After about 10-15 years, incipient diabetic 
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nephropathy develops.  The patient now has microalbuminuria along with the 
glomerular lesions.  This is an important stage of DN because therapeutic 
intervention is started with the goal of preventing progression to overt DN.  In 
overt DN there is worsening proteinuria, a drop in glomerular filtration rate and 
eventual progression to ESRD.  The pathology of overt DN usually consists of 
glomerulosclerosis, fibrinoid caps and arteriolar hyalinosis (226-228).   
In 2008, 44 % of all new cases of kidney failure were a result of diabetes.  
It was estimated over 200,000 people with ESRD due to diabetes were on 
chronic dialysis or living with a transplant in 2008, even though the majority of 
diabetic patients with DN die of cardiovascular causes before progression to 
ESRD.  Treatments for DN are aimed at controlling blood glucose and blood 
pressure (11,201,229).  75 % of adults with diabetes have blood pressure ≥ 
130/80 mm Hg.  Treatment with ACEi or ARBs is more effective at reducing the 
decline in renal function than other blood pressure lowering drugs (217,218).  
According to the CDC, they reduce proteinuria, a risk factor for developing kidney 
disease, by 35 %.  The AT1 receptor is the principal receptor mediating 
angiotensin II pressor effects and is the direct target of ARBs.  AT1 receptor 
activation leads to a number of signal transduction pathways including increases 
in [Ca++]i and activation of cPLA2 (180,181,184-187).  cPLA2 is the rate limiting 
step in prostaglandin synthesis, freeing arachidonic acid from the plasma 
membrane.  COX enzymes catalyze the oxidation and reduction of AA into PGH2, 
which is rapidly converted into one of the principal prostanoids by tissue specific 
synthases. COX-2 expression has been shown to be upregulated in the thick 
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ascending limb and macula densa of both type I and type II diabetic rats (230-
233).  Increased COX-2 expression in the macula densa has also been seen in 
human diabetic kidneys (234).  One product of COX-2 produced PGH2 is the 
prostanoid PGE2, which is of particular interest in diabetes.   
PGE2 has been shown to be elevated in the urine of diabetics, suggesting 
they have increased renal PGE2 production (235).  In STZ and Akita diabetes 
models, renal EP1 and EP3 mRNA expression is increased, suggesting these 
receptors may play an important role in the pathogenesis of DN (236).   
In the Leprdb/db model of diabetes, a homozygous mutation of the leptin 
receptor, treatment with antagonist AH6809 reduced SBP and blocked the 
vasoconstriction of PGE2 and 17-phenyl trinor PGE2, which was enhanced by the 
diabetic phenotype (86).  Furthermore, pharmacologic blockade of EP1 was able 
to ameliorate DN in a rat model of STZ induced diabetes (88).  Treatment with 
the EP1 antagonist was able to reduce renal and glomerular hypertrophy, reduce 
mesangial expansion, and suppress proteinuria (88).  Therefore, we sought to 
determine the contribution of EP1 to DN utilizing a genetic disruption of EP1 in 
mice. 
 
Experimental Procedures 
 
Animal procedures 
Diabetes-induced renal damage was obtained utilizing a previously published 
model involving low dose streptozotocin (STZ) treatment on an eNOS-/- 
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background (195).  Eight week old eNOS-/- mice (EP1+/+, eNOS-/- Jackson 
Labs, USA), EP1-/- , eNOS-/- mice, EP1+/+, eNOS+/+ mice and EP1-/-, eNOS-/- 
mice underwent five consecutive daily i.p. doses of STZ (50 mg/kg).  Two weeks 
after STZ treatment blood glucose was measured by saphenous venesection.  
Diabetic mice with blood glucose greater than 300 mg/dL at 10 weeks of age 
were included in the studies.  Blood glucose, blood pressure, urinary albumin 
excretion, and glomerular filtration rate were assessed 20 weeks after the onset 
of diabetes as illustrated in Figure 5.1.  Animals were maintained in an AAALAC 
accredited rodent facility in individually ventilated microisolator cages on a 12:12 
light dark cycle.  All procedures were done in accordance with the policies of the 
Institutional Animal Care and Use Committee at Vanderbilt University.  
 
Intracarotid blood pressure measurement 
Intracarotid blood pressure was measured under ketamine (25 mg/kg) and 
inactin (100 mg/kg) anesthesia delivered intraperitoneally.  Mice were placed on 
a thermal pad and a PE-10 catheter was inserted into the left carotid artery.  The 
catheter was connected to a TXD-310 transducer and blood pressure was 
measured using a Digi-Med BPA 400  (Micromed).  Mice were equilibrated 30-60 
minutes until stable values were attained.  Ten minute blood pressure 
measurements were collected and average mean arterial pressure (MAP) is 
plotted. 
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Determination of urinary albumin/creatinine ratios 
Albumin/Creatinine ratios (ACR; expressed as mg albumin/mg creatinine) were 
measured from 20-200 μL volumes of spot urine using Albuwell M ELISA kit, and 
urinary creatinine was measured using the Creatinine Companion (Exocell, 
Philadelphia, USA).   
 
 
 
 
 
 
 
Figure 5.1 Induction of diabetes in mice. Eight week old EP1+/+, eNOS-/- mice, 
EP1-/- , eNOS-/- mice, EP1+/+, eNOS+/+ mice and EP1-/-, eNOS+/+ mice 
underwent five consecutive daily i.p.doses of STZ (50 mg/kg).  Diabetic mice with 
blood glucose greater than 300 mg/dL at 10 weeks of age were included in the 
studies.  Blood glucose, blood pressure, urinary albumin excretion, and 
glomerular filtration rate were assessed 20 weeks after the onset of diabetes. 
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Glomerular filtration rate determination 
GFR was determined based on plasma FITC–inulin clearance following a single 
bolus injection (223).   Briefly, dialyzed FITC-inulin solution was injected into tail 
vein.  Approximately 20 µL of blood was collected via saphenous venesection at 
3, 7, 10, 15, 35, 55 and 75 minutes post injection for measurement of FITC 
concentration.  Plasma samples were buffered to pH 7.4 with 500 mM HEPES 
and fluorescence was determined using 485-nm excitation and read at 538-nm 
emission. Parameters were estimated by two-phase exponential decay nonlinear 
regression of plasma fluorescence data (GraphPad Prism). GFR was calculated 
using the equation GFR = I/(A/α + B/β). 
 
Statistical Analysis 
Data are means ± SEM, using GraphPad Prism software (GraphPad Software 
Inc., USA). Analysis utilized Student’s t test. P < 0.05 was considered statistically 
significant for all studies. 
 
Results 
 
Diabetes was induced by low dose STZ treatment 
Diabetic nephropathy was induced in EP1+/+, eNOS-/- mice, EP1-/-, eNOS-/- 
mice, EP1+/+, eNOS+/+ mice and EP1-/-, eNOS+/+ mice by five consecutive 
daily administrations of low dose STZ.  Two weeks after STZ treatment, blood 
glucose was measured and diabetic mice with blood glucose greater than 300 
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mg/dL at 10 weeks of age were included in the studies.  Four and 20 weeks after 
onset of diabetes, blood glucose was measured.  In all genotypes blood glucose 
increased over time, and no differences were observed between the four 
genotypes (Figure 5.2). 
 
 
 
 
 
 
 
Figure 5.2 Diabetes was induced in all genotypes with low dose STZ treatment. 
Blood glucose was measured at onset of diabetes, four weeks diabetic and 
twenty weeks diabetic.  Blood glucose increased with time in all groups, and no 
differences were observed between genotypes (EP1+/+, eNOS+/+ N = 5; EP1-/-, 
eNOS+/+ N = 7; EP1+/+, eNOS-/- N = 3; EP1-/-, eNOS-/- N = 10). 
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MAP was altered by genetic disruption of eNOS and not EP1 
Anesthetized intracarotid blood pressure was measured at 20 weeks post onset 
of diabetes.  No significant differences were observed between any of the 
genotypes (Figure 5.3A).  Genetic deletion of eNOS has been well characterized 
to modestly increase MAP. When MAP was stratified based on eNOS genotype, 
regardless of the status of the EP1 gene, a significant increase in MAP was 
observed (P = 0.027, Figure 5.3B).  
 
Urinary albumin excretion was reduced by genetic ablation of EP1 
Low dose STZ has been demonstrated to induce diabetic nephropathy in 
C57BL/6 mice when eNOS has been deleted (195).  In our study, we also 
observed increased protein excretion in EP1+/+, eNOS-/- mice as compared to 
EP1+/+, eNOS+/+ mice (P = 0.009).  Deletion of the EP1 receptor on the 
background of eNOS-/- reduced urinary protein to a level similar to that observed 
in eNOS+/+ mice (EP1+/+, eNOS-/- vs. EP1-/-, eNOS-/- P = 0.028, Figure 5.4). 
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Figure 5.3 MAP was increased by genetic deletion of eNOS, but no change was 
observed due to EP1 gene disruption.  A.  Average MAP at 20 weeks diabetic.  
Anesthetized intracarotid blood pressure demonstrated no significant differences 
observed between any genotype (EP1+/+, eNOS+/+ vs. EP1-/-, eNOS+/+ P = 
0.294; EP1+/+, eNOS-/- vs. EP1-/-, eNOS-/- P = 0.536; EP1+/+, eNOS+/+ vs. 
EP1+/+,eNOS-/- P = 0.090; EP1-/-, eNOS+/+ vs. EP1-/-, eNOS-/- P = 0.263 by   
t-test).  B.  MAP stratified based on eNOS genotype.  MAP, regardless of EP1 
gene status, was significantly increased with eNOS genetic ablation (P = 0.027). 
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Figure 5.4 Albuminuria was significantly reduced by genetic disruption of EP1 in 
DN.  Urinary albumin excretion was measured at 20 weeks post diabetes.  
Genetic deletion of eNOS significantly increased ACR on the background of 
EP1+/+ (P = 0.009), while no statistically significant increase was observed on 
the EP1-/- background (P = 0.054).  Deletion of EP1reduced ACR on the 
eNOS-/- background (P = 0.028). 
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GFR was reduced by deletion of eNOS in the presence, but not absence of 
EP1 
 
Hyperfiltration is often observed in diabetes.  In our study, we observed GFR of 
approximately 40 µL/min/gram body weight in EP1+/+, eNOS+/+ mice (Figure 
5.5).  Genetic deletion of eNOS significantly reduced GFR to approximately 15 
µL/min/gram (P = 0.0001), indicating compromised renal function.  Genetic 
deletion of EP1 on the eNOS-/- background had no statistically significant effect, 
but trended toward a slightly higher GFR (20 µL/min/gram, P = 0.051).  However, 
genetic deletion of EP1 on the eNOS+/+ background significantly reduced GFR 
(P = 0.011).  No significant reduction in GFR was observed between EP1-/-, 
eNOS+/+ and EP1-/-,eNOS-/- mice (P = 0.301). 
 
Discussion 
 
In the present study we examined whether genetic disruption of EP1 
protected eNOS-/- mice from STZ induced diabetic nephropathy.  We 
demonstrated EP1-/-, eNOS-/- mice have a significant reduction in proteinuria as 
compared to EP1+/+, eNOS-/- control mice.  No significant difference in blood 
pressure was conferred by disruption of EP1 in this model.  Our data are 
consistent a previous report that showed treatment of STZ induced diabetes in 
Wistar rats with EP1 antagonist ONO-8713 reduced renal hypertrophy and 
suppressed proteinuria (88), suggesting the EP1 receptor contributes to renal 
decline in the setting of diabetes. 
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Figure 5.5 GFR was significantly reduced by deletion of eNOS in the presence, 
but not absence of EP1 receptor expression.  GFR was measured at 20 weeks 
post diabetes.  High GFR was observed in EP1+/+, eNOS+/+ mice, and was 
significantly reduced by deletion of eNOS (P = 0.0001) and deletion of EP1-/- (P 
= 0.011).  Deletion of eNOS on the background of EP1-/- had no significant effect 
(P = 0.301).  No statistically significant difference was observed between EP1+/+, 
eNOS-/- and EP1-/-, eNOS-/- mice (P = 0.051). 
 
 
  
108 
 
In our studies we were unable to detect a reduction in blood pressure due 
to disruption of EP1 suggesting suppression of proteinuria occurred by a 
mechanism other than blood pressure regulation.  However, this may be a result 
of small sample size (3-4 mice per group).  Deletion of eNOS conferred an 
average rise in BP of 10 mm Hg, and it may be expected that EP1 disruption 
reduce BP to an intermediate level.  Such small changes would require larger 
sample sizes to measure with statistical significance.  Rutkai et al demonstrated 
that BP and diabetes enhanced vasoconstriction could be reduced in the db/db 
diabetic model by treatment with AH6809 (86).  The authors attribute the results 
to blockade of EP1 receptors although this particular antagonist is not very 
selective.  In Xenopus oocytes expressing human EP1 receptors, AH6809 is able 
to inhibit calcium accumulation (21); in CHO cells stably expressing mouse 
prostanoid receptors AH6809 failed to compete 3H-PGE2 for mouse EP1 (30 % 
displacement at 10 µM), while demonstrating a Ki of 350 nM at mouse EP2 (34).  
It would be interesting whether their results could be reproduced with a more 
selective antagonist such as ONO-8713. 
Another interesting finding uncovered in this study was lower GFR 
observed in EP1-/-, eNOS+/+ mice as compared to EP1+/+,eNOS+/+.  C57BL/6J 
eNOS+/+ mice are resistant to development of diabetic nephropathy, while 
deletion of eNOS renders the strain susceptible (195,237).  We predicted GFR 
would be elevated in both genotypes to a similar degree due to hyperfiltration.  It 
may be possible that EP1-/- mice do not hyperfilter to the same extent as EP1+/+ 
mice.  Alternatively it is possible that EP1 plays an important role in an age 
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dependent reduction in GFR.  At the time GFR was measured, the mice were > 6 
months old.  This hypothesis is consistent with results shown in Chapter IV, 
Figure 4.5B.  EP1-/- 129S6 mice, which were aged from 12 to 18 weeks without 
uninephrectomy or Ang II, displayed a significant reduction in GFR while no 
reduction was observed in EP1+/+ mice.  It would be interesting to determine if 
this trend holds true in repeated experiments or is observed with prolonged 
treatment by pharmacological blockade in a healthy animal.  Use of control 
animals, receiving no STZ, would be of importance in future experiment to 
eliminate hyperfiltration as a confounding variable. 
In summary, our data demonstrate a detrimental role of EP1 in diabetes-
induced proteinuria. This protection may be independent of blood pressure 
reduction.  In addition, it would be of great interest to determine differences renal 
morphology as well.  These results suggest the EP1 receptor may be a viable 
target for the treatment of diabetic renal damage. 
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CHAPTER VI 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Summary 
 
Hypertension is a prevalent disease affecting one in three adults in the 
United States.  It is estimated that 27.5 % of the adult population is either not 
receiving therapy for their hypertension or is unable to control their blood 
pressure with the current therapies, making treatment of hypertension an 
important public health goal. 
PGE2, a biologically active lipid-derived autacoid, contributes to the 
regulation of blood pressure and is able to exert vasopressor or vasodepressor 
effects depending upon the setting (17-19).  EP1 does not appear to play a 
significant role in the blood pressure effects of systemically administered PGE2, 
however, it does contribute to hypertension.  EP1-/- mice have blunted pressor 
responses to both acute and chronic Ang II administration (85).  In isolated 
vessel preparations, pre-treatment with the EP1/EP3 antagonist SC51322 
reduced Ang II mediated vasoconstriction (85).  Treatment of spontaneously 
hypertensive rats with SC51322 significantly reduces blood pressure (85), 
indicating blockade of the EP1/EP3 receptors may be a target for the treatment 
of hypertension.   
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EP1 blockade has been shown to positively affect renal function in stroke-
prone spontaneously hypertensive rats (87), as well as cerebrovascular 
dysfunction induced by Ang II (161), implicating the EP1 receptor in hypertension 
and resultant end-organ damage.  No data exists regarding the contribution of 
the EP3 receptor to hypertensive end-organ damage. 
Three-quarters of diabetic patients have blood pressure ≥ 130 mm Hg, 
and diabetes is the leading cause of chronic kidney failure.  In STZ and Akita 
diabetes models, renal EP1 and EP3 mRNA expression is increased, suggesting 
these receptors may play an important role in the pathogenesis of DN (236).  
Pharmacologic blockade of EP1 was able to ameliorate DN in a rat model of STZ 
induced diabetes (88).  Treatment with the EP1 antagonist was able to reduce 
renal and glomerular hypertrophy, reduce mesangial expansion, and suppress 
proteinuria (88).  However, little advance has been made on the role of EP1 in 
hypertensive and diabetic renal damage, as these studies were published about 
10 years ago, nor have the effects been reproduced with a genetic approach or 
another antagonist.  Therefore, we sought to determine the contribution of EP1 
and/or EP3 receptors to hypertensive end-organ damage and DN using a genetic 
approach in mice. 
Using the Nphx/DOCA-NaCl/Ang II model of hypertension, we have 
demonstrated that disruption of EP1 or EP3 can afford substantial protection 
from end-organ damage and reduce incidence of mortality (Chapter II and 
Chapter III).  The beneficial effects of EP1 disruption, and likely EP3 disruption, 
appeared to be a result of reduction in MAP, since treatment with the 
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antihypertensive agent hydralazine was able to phenocopy the effect observed in 
EP1-/- mice.  Mortality in the Nphx/DOCA-NaCl/Ang II model occurred primarily 
as a result of aortic aneurysm rupture, or after development of anasarca.  We 
hypothesize that hypertension induced by DOCA-NaCl and Ang II results in 
volume loading and enhanced vasoconstriction, which places excessive stress 
on the vascular wall leading to enhanced permeability, resulting in edema and 
susceptibility to dissections and rupture.  While we have shown that protection 
against end-organ damage is likely a result of reduced blood pressure, this does 
not eliminate the possibility that EP1 receptors might also provide protection 
directly at the target tissue, especially given the acute, severe nature of damage 
in this model.   
Previous reports of the role of EP1 in renal injury are contradictory.  In 
spontaneously hypertensive rats, treatment with an EP1 antagonist reduced 
proteinuria and tubulointerstitial damage (87), while in anti-GBM nephrotoxic 
serum nephritis genetic deletion of EP1-/- in mice resulted in enhanced 
mesangial expansion and tubular dilation and increased blood urea nitrogen and 
serum creatinine (173).  In our studies with the Nphx/DOCA-NaCl/Ang II model, 
modest hypertensive renal damage was observed, although no significant 
differences in renal function were detected between genotypes.  However, our 
interpretation was confounded by the differential mortalities in EP1+/+ and EP1-/- 
mice, potentially biasing our results.  Examination of renal histopathology at time 
points prior to significant mortality failed to detect any severe renal damage or 
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differences between the genotypes, suggesting the role of EP1 in renal damage 
is highly context dependent.   
Due to the high mortality and lack of severe renal damage observed in the 
Nphx/DOCA-NaCl/Ang II model, we pursued the use of another model involving 
uninephrectomy and Ang II on a 129S6 background (Chapter IV).  This genetic 
background is more susceptible to development of renal damage, and it therefore 
requires less manipulation to achieve more renal damage.  The uninephrectomy 
and Ang II model resulted in functional renal damage including a rise in BUN, 
elevated ACR and reduced GFR.  Genetic ablation of EP1 reduced the rise in 
BUN and ACR while no change in hypertension was observed. This suggests the 
EP1 receptor plays an important role in hypertensive renal disease independent 
of blood pressure reduction. However, throughout these studies blood pressure 
was measured by tail cuff plethysmography.  It is possible that blood pressure 
differences were not observed in our studies due to the lack of sensitivity of the 
tail cuff technique.   
Lastly, we examined whether genetic disruption of EP1 protected eNOS-/- 
mice from STZ induced diabetic nephropathy (Chapter V).  We demonstrated 
EP1-/-, eNOS-/- mice have a significant reduction in proteinuria as compared to 
EP1+/+, eNOS-/- control mice.  No significant difference in blood pressure was 
conferred by disruption of EP1 in this model.  Our data are consistent a previous 
report that showed treatment of STZ induced diabetes in Wistar rats with EP1 
antagonist ONO-8713 reduced renal hypertrophy and suppressed proteinuria 
(88), suggesting the EP1 receptor contributes to renal decline in the setting of 
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diabetes.  Again, we were unable to detect a reduction in blood pressure due to 
disruption of EP1 suggesting suppression of proteinuria occurred by a 
mechanism other than blood pressure regulation.  Although blood pressure was 
measured using a direct intracarotid catheter, the lack of a difference may be a 
result of small sample size (3-4 mice per group).   
Another interesting finding uncovered in these studies points to a potential 
role of the EP1 receptor in age-dependent renal decline.  In the diabetic renal 
model (Chapter V), lower GFR was observed in EP1-/-, eNOS+/+ mice as 
compared to EP1+/+, eNOS+/+.  At the time GFR was measured, the mice were 
> 6 months old.  Furthermore, in the hypertensive renal model (Chapter IV), 
EP1-/- mice began the study with significantly higher BUN as compared to 
EP1+/+ mice.  Similarly GFR declined with age in untreated EP1-/- mice and not 
EP1+/+ mice.  This effect has not been observed previously, and it would be 
important to determine if this trend holds true in repeated experiments or is 
observed with prolonged treatment by pharmacological blockade in a healthy 
animal.  This could indicate that treatment with EP1 antagonists would be better 
utilized for slowing the progression of renal damage and not advised for use in 
patients without renal damage. 
In summary, our data demonstrate a detrimental role of EP1 in 
hypertensive and diabetic end-organ damage.  Further characterization of EP1 in 
these diseases will be essential as the EP1 receptor may be a viable 
pharmaceutical target for the treatment of hypertension and subsequent organ 
damage.  
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Future directions 
  
The data presented in this thesis advances our knowledge of the role of 
EP1 and EP3 receptors in hypertension and subsequent sequalae.  Several new 
questions have emerged as a result including:  Does the EP1 receptor mediate 
the BP- independent actions of Ang II?  What is the therapeutic relevance of EP1 
blockade?  What is the contribution of EP1 in vascular permeability?  Which EP 
receptors contribute to aortic aneurysm formation? What is the mechanism of 
EP1/Angiotensin II hypertension?  Future experiments should be designed to 
address these issues. 
Drugs which block the renin-angiotensin-aldosterone pathway are 
considered superior to other anti-hypertensive treatments due to their beneficial 
actions directly on the kidney which occur independent of blood pressure 
reduction.  Additionally, PGE2 and the EP1 receptor have been demonstrated to 
mediate at least part of the actions of angiotensin II.  It would be of great interest 
to determine whether genetic disruption of EP1also confers similar protection in 
the kidney.   Preliminary studies presented in this thesis (Chapters IV and V) 
suggest this may be the case.  Disruption of EP receptors suppressed increases 
in proteinuria and BUN or prevented reductions in GFR, while no significant 
differences in blood pressure were detected.  However, throughout these studies 
blood pressure was measured by tail cuff plethysmography or contained small 
sample sizes of direct intracarotid measurements.  It is possible that blood 
pressure differences were not observed in our studies due to the lack of 
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sensitivity or low power.  To address this, future experiments should include 
more accurate blood pressure measurements using a direct arterial catherization, 
in either anesthetized mice or by telemetry.  Additionally, the therapeutic 
relevance of EP1 blockade should be more thoroughly characterized.  One major 
limitation associated with the use of genetic disruption verses pharmacologic 
blockade is the chronic disruption of receptor action.  Lack of receptor action 
throughout development or in the absence of disease may result in 
compensatory changes which may not be observed with use of pharmacologic 
agents.   Therefore, determining whether similar results can be obtained by 
treatment with an EP1 antagonist would be essential for verifying the therapeutic 
benefit of EP1 blockade.  Furthermore, it would be of interest to determine 
whether there is additional benefit from dual EP1/EP3 blockade compared with 
EP1 or EP3 blockade only.  The mechanism by which EP1 and EP3 mediate 
hypertension in unknown, however it is well understood that the EP1 and EP3 
can mediate distinct signal transduction pathways.  It is conceivable that 
blockade of EP1 and EP3 may have an additive effect and provide enhanced 
protection. 
For the uninephrectomy/ DOCA-NaCl/Ang II model, we hypothesized that 
hypertension resulted in enhanced vascular permeability, causing edema and 
susceptibility to dissections and rupture (Chapter II).  This hypothesis was based 
on eliminating the most common causes of edema.  Furthermore both 
aneurysms and edema were reduced via treatment with hydralazine, supporting 
hypertension as the major mitigating factor for development of these pathologies.  
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Future experiments will be required to identify whether vascular permeability 
differences are observed between EP1+/+ and EP1-/- mice.  In this model, 
vascular permeability could be examined using Evans Blue dye or dextran-
rhodamine permeability.  If differences were observed in vivo, the molecular 
mechanism could be identified using transwell vascular permeability assays, with 
cells isolated from EP1+/+ and EP1-/- mice or heterologously expressing EP1. 
It has been previously shown that either selective inhibition of COX-2 or 
genetic deletion of COX-2 significantly reduced aortic aneurysm formation and 
macrophage infiltration (166,167).  Furthermore, deletion of microsomal PGE 
synthase-1 has also been demonstrated to reduce aortic aneurysm formation 
and oxidative stress in LDLR-/- mice with an angiotensin II infusion (160), 
suggesting PGE2 plays an important role in development of aneurysms and the 
EP receptors may be viable targets for treatment of aneurysm progression.  It 
would be of interest to investigate the contribution of EP1 in vascular damage, 
utilizing models which are independent of increased blood pressure, such as wire 
injury. 
Lastly, it is imperative that we identify the mechanism by which EP1 and 
EP3 mediate Ang II-induced hypertension.  It has been demonstrated that Ang II-
induced vasoconstriction can be blocked by treatment with EP1/EP3 antaogonist 
SC-51322.  EP1 receptors in the sub-fornical organ of the brain also play a 
critical role in slow pressor Ang II hypertension (238).  Ang II/EP1 signaling in the 
subfornical organ is dependent of COX activity, suggesting that Ang II results in 
local production of PGE2, which then activates EP1 (238).  It would be interesting 
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to determine whether a similar mechanism/interaction is observed in other target 
tissues such as the kidney.  Furthermore, the mechanism of EP3 action in Ang II-
mediated hypertension is still unknown but may have an important contribution in 
Ang II-induced vasoconstriction.  Future experiment designed to address these 
remaining questions would increase our overall understanding of EP receptors in 
blood pressure regulation, and may also uncover new therapeutic targets for the 
treatment of hypertension and end-organ damage. 
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